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Melanoma is responsible for 76% of deaths from skin cancer, making it the deadliest form of 
commonly diagnosed skin cancer. The deadly nature of melanoma is due to its tendency towards 
rapid metastasis early in tumor progression. Metastasis is the process of cells exiting the primary 
tumor and forming secondary tumors in other parts of the body. Metastasis accounts for as much 
as 90% of morbidity and mortality associated with cancer. Therapeutically targeting and treating 
melanoma metastases is a challenging clinical goal, as metastatic cells are heterogeneous and can 
be morphologically and genetically distinct from the primary tumor. This dissertation examines 
two distinct approaches towards preventing or treating disseminated melanoma metastases: 1) 
Re-introduction of metastasis suppressor protein fragments to prevent metastatic colonization, 
and 2) Treating disseminated metastases with a targeted small molecule treatment. By examining 
two discrete approaches of treating metastatic melanoma, this work sheds light on the clinical 
viability of using metastasis suppressors or metastasis-targeting drugs in patients with metastatic 
melanoma.   
        To examine strategies for metastasis suppression through metastasis suppressor proteins, 
we examined fragments of KISS1. Expression of KISS1 inhibits metastatic colonization at 
secondary sites, rendering disseminated cells dormant. KISS1 must be secreted outside of the 
cell to suppress metastasis, where furin cleaves KISS1 into kisspeptins at three dibasic sites. This 
cleavage liberates an internal kisspeptin, Kisspeptin-54 (KP54, K67 to F121), which is amidated and 
can bind a Gq/11-coupled protein receptor KISS1R. The mechanism of action for KISS1 metastasis 
suppression has long been assumed to be KP54 interacting with KISS1R. However, expression 
of KISS1R is not necessary for KISS1 metastasis suppression, and the extracellular processing of 
KISS1 hints at an alternative hypothesis: a different kisspeptin may be responsible for 
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suppressing metastasis. To test this hypothesis, all possible kisspeptins (KISS1 Manufactured 
Peptides, or KMP) were generated based on known dibasic cleavage sites (M1–Q145; M1–R56; M1–
R67; M1–R124; R56–R66; R67-F121; R56–F121; R56–Q145; R67–Q145; R124–Q145) and were used in an experimental 
metastasis assay to characterize their abilities to suppress metastasis. We found that while KP54 
suppressed metastasis, additional KMP lacking the KISS1R binding site (LRF-NH2) were able to 
completely suppress metastasis (p<0.05). In particular, one kisspeptin (KMP2, M1 – R56) 
suppressed metastatic traits in vitro as well as completely suppressing metastasis in vivo. To 
identify the signaling pathways used by KMP2 to suppress metastasis, a genome wide 
CRISPR/Cas9 screen was performed in KMP2-expressing B16-F10 melanoma cells. As a whole, 
these data suggest that metastasis suppression by KISS1 is not necessarily contingent on KISS1R 
activation, and also supports investigation into additional receptors. 
 To investigate the efficacy of targeting metastases with small molecules, we also 
investigated the impact of ML246 (AKA metarrestin). Metarrestin was discovered by a high 
throughput assay for molecules which disassemble the perinucleolar compartment (PNC). 
Perinucleolar compartments are structures composed of RNA and RNA binding proteins near the 
nucleolus. These structures are enriched in metastatic cells and are druggable targets which target 
metastases and not normal epithelium. We examined the impact of metarrestin treatment on 
orthotopic tumor growth, microscopic metastasis formation, and macroscopic metastasis 
formation. We found that metarrestin treatment had no significant impact on metastatic 
outgrowth, but suppressed intradermal tumor growth. Based on these data, we can infer that 
PNC-positive metastases may be too small a population to effectively target in this model of 
metastatic melanoma. This treatment paradigm may be more effective in conjunction with a 
more potent approach to metastasis suppression.  
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Overall, the work in this dissertation identified a potent metastasis suppressing peptide 
fragment of KISS1, KMP2, and described the efficacy of metarrestin treatment of disseminated 
melanoma metastases. The metastasis suppression induced by KMP2 expression was far more 
potent than the effects of metarrestin treatment, suggesting that treatment deliveries and targets 
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Cancer and metastasis 
 Cancer, is steadily gaining ground as a worldwide epidemic. An estimated 1 in 7 deaths 
worldwide is attributed to cancer, and over 60% of these deaths occur in low- and middle-income 
countries which lack adequate healthcare resources and infrastructure (Siegel, Miller, & Jemal, 
2016). In the United States, cancer is the leading cause of death in 21 states, which is largely due 
to decreases in death from other causes (Siegel et al., 2016). Despite prevention and early 
detection technologies becoming more widespread, cancer promises to burden the global 
healthcare system as the population ages. By the year 2030, an estimated 21.7 million new 
cancer cases and 13 million cancer deaths are expected to occur. To stem the tide of cancer, a 
better understanding of the disease itself is necessary. 
 Cancer is defined as the abnormal behavior of a cell which can result in uncontrolled 
growth or death. Cancer is generally thought to arise from a combination of internal (e.g. 
inherited genetic mutations, inflammation, hormones, immune conditions, etc.) and 
environmental factors (smoking, pollution, exposure to carcinogens, UV radiation, etc.).  Of all 
cancer diagnoses in the United States, the top three diagnosed cancers are breast cancer (female), 
prostate cancer, and lung/bronchus (Siegel et al., 2016). Better early detection methods in breast 
cancer and prostate cancer (mammograms and prostate exams, respectively) have helped to 
detect these cancers early to reduce mortality. Lung cancer continues to be a prominently 
diagnosed cancer due to population smoking trends (Kochanek, Murphy, Xu, & Tejada-Vera, 
2016). Globally, cancer incidence and deaths continue to climb despite better attempts to prevent 
and detect it early.  
 Most types of cancer are not inherently deadly. Cancers which are detected early have a 
much lower mortality rate than more progressed tumors. It is later in the process of tumor 
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progression, when a cancer metastasizes, that cancer becomes deadly. Metastasis, the multi-step 
process of cells exiting the primary tumor to form secondary tumors, is the cause for as much as 
90% of the morbidity and mortality associated with cancer. Metastatic cancers become deadly 
when secondary tumors disrupt tissue function throughout the body. If metastasis could be 
prevented, managed, or delayed, cancer could be managed more like a chronic disease. Wholly 
preventing or curing cancer on a population-scale is an unlikely goal, but finding a way to stop, 
prevent, or treat metastasis as a chronic condition is a more attainable clinical goal.  
 Metastasis can occur in three general ways. Cells can metastasize through the 
bloodstream, the lymphatic system, or across body or organ cavities. Advances in biomarker 
technology, circulating tumor cell detection, cell-free DNA detection, and tumor deep 
sequencing have shed light on which cancers are likely to metastasize, but the need to more 
precisely identify patients with metastatic tumors remains. Patients with more aggressively 
metastatic cancer types require a more aggressive treatment as opposed to patients with a 
localized, non-metastatic tumor type. Identifying biomarkers or other signs of metastatic 
propensity would improve treatment accuracy and precision for cancer patients.  
The metastatic cascade 
 The process of metastasis is complex and involves a series of interdependent steps, which 
are cumulatively referred to as the metastatic cascade. Failure to complete even a single step in 
the metastatic cascade results in cell death. While tumors can shed upwards of one million cells 
into the bloodstream per day, very few of these cells successfully complete the metastatic 
cascade (Weiss, 1990). These sequential steps selectively enrich for a population of highly 










   
Figure 1: The major steps of the metastatic cascade for solid tumors. Figure adapted 
from Francia et. al (2011) 
6 
 
  Tumors begin to shed cells early during tumor progression, but metastases are 
more likely to be detected from more advanced tumors (Butler & Gullino, 1975). As tumors 
begin to grow and divide, they quickly outgrow the nutrient supply available in the stromal 
tissue. construction of novel vasculature around the tumor. Oxygen can diffuse 150-200 microns 
through a tissue, which results in the core of even small tumors quickly becoming hypoxic. 
Hypoxia, the state of tissues in a low oxygen environment, induces the stabilization of hypoxia 
inducible factors 1 and 2 (HIF1 and HIF2), which are transcription factors which target genes 
that allow cells to survive in times of nutritional depletion (Semenza, Roth, Fang, & Wang, 
1994). These HIF proteins drive a transcriptional profile upregulating angiogenic factors such as 
VEGF, which is secreted into the microenvironment and stimulates blood vessel formation (Y. 
Liu, Cox, Morita, & Kourembanas, 1995; Mazure, Chen, Yeh, Laderoute, & Giaccia, 1996). The 
formation of a tumor-supporting vasculature allows tumors to shuttle nutrients in and waste 
products out. The vasculature formed by this process is noteworthy for its “leakiness,” or the 
gaps in the endothelial wall. These gaps in the endothelium facilitate easier transition of nutrients 
or cells in and out of the vasculature, as well as allowing for easy formation of new vascular 
sprouts.  These angiogenic activities facilitate further growth and invasion in the tumor. 
 With the nutritional support system generated from angiogenesis, tumors now can 
continue to grow and invade into the surrounding stromal tissue. As tumors grow into the stroma, 
they secrete enzymes such as collagenases and matrix metalloproteases that degrade the 
microenvironment. These enzymes work to clear additional space for tumor outgrowth. In 
concert with the secretion of proteolytic enzymes, tumors also secrete other factors to condition 
the microenvironment to preferentially support tumor outgrowth. Prominent secreted factors 
such as VEGF and CXCL-family chemokines create a chemoattractive gradient which recruits 
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endothelial cells and immune cells (Roodman, 2004). Tumors, which rely heavily on glycolytic 
metabolism, also secrete lactate as a glycolytic by-product. Lactate acidifies the tumor 
microenvironment, conditioning the surrounding stromal tissue which has been found to support 
tumor growth and metastasis (Song et al., 2015). Tumors secrete a proteolytic, inflammatory, 
acidic milieu to shape their surroundings in a manner which favors growth and metastasis.  
 Invasive tumors can eventually shed cells which migrate out of the immediate tumor 
microenvironment, invade the basement membrane, and intravasate into the vasculature or 
lymphatic system. This step of metastasis, cells exiting the primary tumor, can begin early in 
tumor progression, but is more highly associated with larger tumors. To exit the tumor, cells 
must physically migrate away from the tumor and squeeze between or through epithelial or 
endothelial cells (Liotta, 1986; Wolf et al., 2003). To migrate, metastatic cells must dynamically 
reorganize their actin cytoskeleton to facilitate movement (Brinkley et al., 1980; Volk, Geiger, & 
Raz, 1984). Cells form focal adhesions by phosphorylation of focal adhesion kinase (FAK) and 
integrin binding to adhere to anchors in the microenvironment as they travel through the stroma 
(Huttenlocher et al., 1998; Ruoslahti, 1994). Migratory cells will extend projections, form 
adhesions, and then use the actin-myosin cytoskeleton to pull the rest of the cell through the 
tissue.  
 There are two primary mechanisms of invasion: individual cell migration and collective 
cell migration (Friedl, Locker, Sahai, & Segall, 2012). Individual cell migration is characterized 
by single cells invading the surrounding tissue and escaping the tumor as individual units. 
Collective cell migration, however, describes a phenomena where a cluster of cells collectively 
invades surrounding tissue while retaining cellular junctions (Friedl et al., 2012). Carcinomas, a 
cancer type originating from epithelial cells, tend to invade through collective cell migration 
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(Friedl et al., 2012). Sarcomas, cancers which arise from mesenchymal cells such as 
melanocytes, muscle cells, bone, and neurons, tend to instead invade using individual cell 
migration (Wolf et al., 2003). These cells lack cellular junctions and invade the surrounding 
tissue as single cells. Either mechanism of invasion can result in cells escaping the tumor, 
invading surrounding tissue, and crossing the basement membrane. From here, cells can 
intravasate into the bloodstream or the lymphatic system. 
 Within the bloodstream or lymphatic system, metastatic cells encounter a new host of 
challenges. These migratory cells must evade immune detection from circulating and tissue-
associated immune cells. One mechanism to avoid immune detection is metastatic cells can coat 
themselves with platelets to avoid immune surveillance. Within this platelet-tumor cell 
aggregate, the cells are held together with integrin bridges, which deters detection by natural 
killer cells (Tesfamariam, 2016). Once they enter the circulatory system, metastatic cells must 
also withstand the immense pressure of vascular shear forces, which can tear most epithelial cells 
apart (Wirtz, Konstantopoulos, & Searson, 2011). Resistance to mechanical stress is recognized 
as a key characteristic for successful metastatic cells both in the bloodstream and in the stroma 
(Kumar & Weaver, 2009). Within the circulation, metastatic cells must also resist anoikis, an 
apoptosis program initiated by a lack of anchorage. Many metastatic cells overcome this by 
overexpressing mitochondrial anti-apoptotic proteins such as Bcl-2, Bcl-XL, and Mcl-1 and/or 
downregulating pro-apoptotic proteins such as Bax and the caspaces (Patel, Camacho, Shiozawa, 
Pienta, & Taichman, 2011).  Resistance to mechanical stressors in the vasculature and evasion of 
the immune system are major bottlenecks to the metastatic cascade. 
 Even metastatic cells do not linger indefinitely in the circulatory or lymphatic systems. 
The cells require a stationary setting to form full-fledged metastases. Early metastases are often 
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identified in lymph nodes proximal to the primary tumor (Greenblatt, 1933). However, the 
determination of metastatic sites is not exclusively proximity-based. Melanomas can metastasize 
to different sites in the skin, and bladder cancer cells can metastasize across the bladder to 
another site on the bladder. However, many metastases target the lung, bone, and brain (Babaian, 
Johnson, Llamas, & Ayala, 1980). The exact factors which contribute to the metastatic site are 
not fully understood, however the affinity of certain cancers to metastasize to these sites suggests 
that these microenvironments are conducive to metastatic outgrowth. In 1889, Paget noted the 
predisposition of certain cancers to metastasize to certain sites (Paget, 1889). This site-specific 
metastasis was described as the interaction of the correct “seed” (cancer cell) reaching a 
“congenial soil,” or a tissue where disseminated cells could survive and thrive. The discovery of 
tissue-specific addressins, molecules which lymphocytes use to target specific tissues supports 
that metastatic cells could also selectively express surface markers to target metastatic sites 
(Kieran & Longenecker, 1983; Nakache, Berg, Streeter, & Butcher, 1989; Ruoslahti, 1994). 
Once these cells reach the appropriate secondary site, they are primed to enter the final phase of 
the metastatic cascade.   
 Upon reaching these sites, metastatic cells either lodge themselves in a capillary or 
adhere to the vessel wall and extravasate. After lodging in the capillary or extravasating into the 
secondary tissue, the cells then colonize the tissue and divide to form full-fledged metastases. 
This change in environment requires a change in cellular behavior. While migrating, and 
traveling through the lymph or circulatory systems, metastatic cells do not tend to divide. 
However, upon reaching a secondary site, metastatic cells require a change in behavior to divide 
and form macroscopic metastases. This switch from a migratory, mesenchymal phenotype back 
to an epithelial phenotype is often referred to as MET, or mesenchymal to epithelial transition 
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(Auersperg et al., 1999). This phenomenon is observed in normal physiology during 
development, and cancer cells recapitulate this behavior at the last phase of the metastatic 
cascade. The metastatic cells can then switch to a dividing, tumor-like phenotype to successfully 
form metastases.  
 However, metastases do not necessarily form macroscopic metastases. Once metastatic 
cells have seeded a secondary tissue, they can lie dormant, sometimes for months or years 
(Alexander, 1983; Celia-Terrassa & Kang, 2016; Romero, Garrido, & Garcia-Lora, 2014; Stein-
Werblowsky, 1978; Sugarbaker, Ketcham, & Cohen, 1971). Metastatic dormancy is generally 
attributed to the adaptation of disseminated tumor cells to an unfamiliar microenvironment 
(Giancotti, 2013). A key characteristics of single-cell metastatic dormancy is cell cycle arrest, 
often due to mitogenic signaling from host tissue (Osisami & Keller, 2013). Dormant metastatic 
cells can linger in quiescence or recover and resume division. 
 The metastatic cascade is complex and incredibly inefficient. For metastases to form, 
each of these steps must be successfully completed. Even though tumors can shed upwards of 
one million cells per day, patients do not present with millions of metastases. Yet despite this 
lack of efficiency, metastasis still occurs and is the main cause of cancer-associated mortality. 
Metastases which survive the metastatic cascade have evaded the immune system, withstood 
shear forces of the bloodstream, selected and conditioned a new tissue, and created their own 
metastatic niche. The survivors of the metastatic cascade are cells, later tumors, which are 
uniquely suited to thrive in a new environment.   
Clinically targeting metastasis 
Clinically targeting metastasis remains an elusive goal. Metastases are challenging to target, as 
they often have different characteristics from their primary tumors. To complete the steps of the 
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metastatic cascade and become metastases, metastatic cells must behave differently from tumor 
cells. Therefore, to therapeutically target metastases, it is necessary to utilize targeted therapies 
to detect and treat metastases. Targeted anti-metastatic therapies generally consist of neutralizing 
antibodies and small molecule kinase inhibitors. While these therapies can be specifically 
targeted based on the genetic composition of the primary tumor, these therapies are not the 
complete answer to the problem of metastasis. Tumor heterogeneity notwithstanding, it is 
established that metastases have a higher accumulation of mutations than primary tumor cells 
(Cifone & Fidler, 1981; Tlsty, Margolin, & Lum, 1989). Because of this inherent genomic 
instability, targeting multiple metastases from the same primary tumor can have varying 
outcomes. A mutation found in the primary tumor could be absent in metastases, rendering 
targeted therapies without a target. Some therapies can be lackluster in most patients but 
demonstrate a striking response in a small subpopulation. Overall, by utilizing the characteristics 
that allow metastases to be successful in the first place, metastatic cells also evade treatment and 
therapy.  
Melanoma 
Melanoma deserves recognition as a cancer which is unique in its predisposition to metastasis as 
well as its steadily increasing incidence since 1950 (Balch, 1992). Melanomas arise from 
melanocytes, cells from the basal layer of the epidermis which produce melanin in response to 
UV exposure. Melanin, which comes in forms of eumelanin and pheomelanin, is thought to be an 
oxidant of UV radiation. Most melanomas arise from a mutational profile traced back to a 
signature indicative of UV damage, a C  T mutation at dipyrimidine sites (Brash et al., 1991). 
These mutations can accumulate in tumor suppressor genes such as p53 or PTEN, as well as 
oncogenic drivers such as BRAF or NRAS and give rise to a transformed melanocyte (Brash et 
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al., 1991; Pierceall, Mukhopadhyay, Goldberg, & Ananthaswamy, 1991).  Early in melanoma 
tumor progression, melanomas undergo an epidermal horizontal (or radial) growth phase where 
the tumor cells remain in the epidermis and simply grow out horizontally through the epidermal 
stroma. The radial phase is then followed by the vertical growth phase, characterized by 
melanoma cells breaking through the epidermis and into the dermal layer. Melanomas in the 
vertical phase of tumor progression are most likely to metastasize, but all melanomas are 
presumed to be aggressive due to the developmental origins of melanocytes. 
Melanocytes are mesenchymal cells which arise from the neural crest during embryonic 
development. During development, melanocytes travel along the neural crest to their destination 
in the embryo. Postnatally, melanocytes are not transcriptionally programmed to migrate or 
travel from their locations. However, in response to DNA damage or other transformative events, 
melanocytes regain their mesenchymal phenotypes and migrate, invade, and intravasate early 
during melanoma tumor progression. Melanomas are considered the most metastatic and deadly 
skin cancer due to this aggressively metastatic nature.  
Metastasis suppressors  
One method to help distinguish metastatic tumors from less aggressive tumors is the presence of 
metastasis suppressors. Metastasis suppressors are a growing family of endogenously expressed 
proteins and RNA that block one or more steps of the metastatic cascade. When expressed by a 
tumor, metastasis suppressors do not have a substantial impact on primary tumor growth (growth 
inhibition of <50% is the generally accepted metric). The first metastasis suppressor, Nm23-H1, 
was discovered in 1988 as a metastasis suppressing gene with the ability to suppress metastasis 
in murine K-1735 melanoma cells (Steeg, Bevilacqua, Kopper, et al., 1988; Steeg, Bevilacqua, 
Pozzatti, Liotta, & Sobel, 1988). Since this discovery, the field has expanded to include several 
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Nm23 family members as well as the more than 30 additional members of the validated 
metastasis suppressor family. These metastasis suppressors have potential to be used as a marker 
of prognosis or a measure of aggressiveness in certain tumor types. There even exists the 
opportunity to use metastasis suppressors as a form of clinical intervention.  
Metastasis suppressors all have normal physiological roles, but many suppressors only suppress 
metastasis in a specific tumor type. As cancer develops, the expression of metastasis suppressors 
is often silenced or deleted during tumor progression. This silencing can be accomplished 
through epigenetic regulation (e.g. methylation), or mutation and silencing due to genomic 
instability (e.g. mutation or chromosomal deletion) (Shirasaki, Takata, Hatta, & Takehara, 2001; 
Steeg, Ouatas, Halverson, Palmieri, & Salerno, 2003). Most metastasis suppressors have an 
effect at multiple steps of the metastatic cascade, while a smaller number selectively inhibit a 
specific step of the metastatic cascade (Bohl, Harihar, Denning, Sharma, & Welch, 2014).  The 
ultimate outcome is that tumors expressing metastasis suppressors tend to have less incidence of 
metastasis and overall improved prognosis. Metastasis suppressors represent a potent, natural 
defense against metastasis.   
The idea of utilizing metastasis suppressors clinically has been discussed since the field was 
established. Many metastasis suppressors have been clinically observed in relation to patient 
prognosis and have prognostic or therapeutic potential (Bohl et al., 2014; Nash & Welch, 2006). 
A loftier goal than predicting prognosis would be to use metastasis suppressors as a tool to 
prevent or treat metastases using metastasis suppressors. To clinically utilize metastasis 
suppressors, there are two general approaches: 1) target pathways used by metastasis suppressors 
with small molecules to recapitulate metastasis suppressor signaling, or 2) re-introduce 
metastasis suppressors, via exogenous administration or gene therapy, back into metastatic 
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lesions. The problems with targeting metastasis suppressor signaling are the lack of knowledge 
the field has gained on the exact mechanisms of these molecules. While the primary functions of 
many metastasis suppressors are understood in normal physiology, several metastasis suppressor 
mechanisms of action remain unelucidated. Embarking on a treatment strategy without the full 
understanding of a mechanism is problematic and unrealistic. There are also inherent challenges 
associated with treatment via metastasis suppressor. Gene therapy directed at metastases requires 
the ability to selectively target metastases. Exogenous administration of metastasis suppressors 
would require a cell-penetration mechanism (such as TAT) for intracellular metastasis 
suppressors. Extracellular metastasis suppressors would require stabilizing and potentially 
metastasis-targeting components to ensure delivery. While the goal of clinically harnessing 
metastasis suppressors remains alive, this goal requires a selective set of circumstances to work. 
A likely metastasis suppressor candidate for therapeutic development would be a secreted or 
extracellular metastasis suppressor.  
KISS1: Metastasis suppressor 
After observing that metastatic melanomas frequently present with deletions of chromosome 6, it 
was observed that re-introduction of a normal human chromosome 6 into metastatic melanoma 
cells suppressed metastasis by 95% (Miele et al., 1996; Welch et al., 1994). This discovery 
suggested that there were metastasis suppressing genes present on chromosome 6. To identify the 
responsible gene(s) of chromosome 6 involved in metastasis suppression, subtractive 
hybridization of cDNAs resulting from re-introduction of different regions of chromosome 6 was 
performed. The finding from this study was KISS1, a 1.0 kB transcript only expressed in 
metastasis-suppressed melanomas with re-introduction of chromosome 6 (Lee et al., 1996; Lee & 
Welch, 1997a).  An analysis of normal melanocytes and radial growth phase melanomas 
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identified endogenous KISS1 expression, but this detection of expression was lost in vertical 
growth phase melanomas or metastatic lesions (Lee et al., 1996). Cumulatively, these data led to 
the conclusion that KISS1 was a gene responsible for metastasis suppression, and that it was 
likely located on chromosome 6.   
In 1998, the chromosomal localization of KiSS-1 was found to be on chromosome 1q32, not 
chromosome (West, Vojta, Welch, & Weissman, 1998). The necessary element on chromosome 
6 was later identified as CRSP3, an upstream regulator of KiSS-1 expression (Goldberg et al., 
2003). Expression of CRSP3 on chromosome 6 was found to be inversely correlated with 
metastatic potential and TXNIP expression, a thioredoxin-binding protein also found on 
chromosome 1 (Shirasaki et al., 2001). TXNIP is a downstream target of CRSP3.  Expression of 
TXNIP is positively correlated with expression of KISS1 and metastasis suppression, and is lost 
when CRSP3 is depleted. These data identified why the loss of chromosome 6 in melanoma led 
to increased metastatic potential, and shed light on KiSS-1 upstream regulation. These findings 
were not limited to melanoma, however. Not long after its discovery, KiSS-1 was also found to 
be a potent metastasis suppressor in breast cancer cells, which opened the door to the possibility 
for KiSS-1 being a metastasis suppressor gene in several cancer types (Lee & Welch, 1997b). 
The multi-functionality of KiSS-1 as a metastasis suppressor gene suggested a potential clinical 
significance for it, either as a biomarker or as a basis for a therapeutic. 
The understanding of how the KiSS-1 metastasis suppressor gene functioned was a mystery for 
several years after its discovery. Analyses of the KiSS-1 cDNA transcript found that KiSS-1 
encoded a 145-amino acid peptide with a 19-amino acid secretion sequence (Lee et al., 1996). 
The peptide sequence also predicted a SH3 binding sequence, prohormone convertase processing 
sites, and a putative protein kinase C phosphorylation site (Lee et al., 1996).  These hints buried 
16 
 
in KiSS-1’s peptide sequence, hereafter KISS1, did not shed light on how the peptide itself 
suppressed metastasis. In 2001, three groups independently investigating orphaned G-protein 
coupled receptors identified that an internal fragment of KISS1 was the ligand for a rat G-protein 
coupled receptor denoted by three names: GPR54, AXOR12, and hOT7T175 (Kotani et al., 
2001; Muir et al., 2001; Ohtaki et al., 2001). This internal fragment of KISS1, metastin or later 
KP54, was an internal 54-amino acid peptide nestled between two dibasic cleavage sites (Ohtaki 
et al., 2001). These groups definitively demonstrated that KP54, and specifically its 10 C-
terminal amino acids, was the ligand to GPR54/AXOR12/h0T7T175, which is now commonly 
known as KISS1R. 
KISS1 processing 
In identifying KP54/metastin as the ligand to KISS1R, these groups consequently shed light on 
KISS1 processing. The secretion sequence and presumptive dibasic sites were indeed processing 
elements to KISS1. When KISS1 is translated, it is secreted outside of the cell through the Golgi 
apparatus (Harihar, Pounds, Iwakuma, Seidah, & Welch, 2014; Nash et al., 2007). Before 
secretion, gamma secretase cleaves the 19-amino acid secretion sequence and KISS1 is then 
shuttled outside of the cell. KISS1 must be secreted outside of the cell to suppress metastasis, 
which cements its role as an extracellular protein (Nash et al., 2007). Once outside of the cell, 
KISS1 is then cleaved by furin, a ubiquitously expressed prohormone convertase, at three dibasic 
sites (R/K-XX-K/R) into kisspeptins (Harihar et al., 2014). Interestingly, furin is expressed 
throughout the cell and even in the Golgi apparatus, yet it is only once KISS1 is outside of the 
cell that this processing occurs (Harihar et al., 2014). Fragments of KISS1 that have been 
identified from tissue all seem to originate from KP54. The peptides identified have primarily 
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Figure 2: A, Diagram of KISS1, secretion sequence (diagonal lines) and cleavage 
sites. KP54 is depicted below with LRF-amide KISS1R binding motif. B, Western blot 
of whole cell lysate (WCL) and conditioned media (CM) immunoprecipitation from 
vector (V), KISS1 (K), and Δ SS-KISS1 (Δ), a non-secreted mutant.  The banding 
pattern observed in conditioned media sample indicates the presence of kisspeptins.  
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peptides, named for their length, are KP-14, KP-13, and KP-10 (Bilban et al., 2004; Maguire et 
al., 2011; Mead, Maguire, Kuc, & Davenport, 2007). The smallest bioactive fragment of KP54 
with the ability to bind KISS1R is KP10, the final 10 amino acids of KP54. KP10 binds KISS1R 
with a higher affinity than even KP54. These processing elements appear to be the normal, 
endogenous KISS1 processing elements necessary for KP54 liberation outside of the cell. Once 
furin cleaves KISS1, PAM amidates F121 and increases the affinity of KP54’s C-terminal domain 
for KISS1R binding (Ohtaki et al., 2001). While the C-terminal amidation at F121 is optimal for 
receptor binding, the un-amidated KP54 is still able to bind KISS1R (Ohtaki et al., 2001).  These 
processing events result in KISS1 and kisspeptins secreted outside of the cell and primed for 
bioactivity.  
There is a biological system in place to negate KISS1 processing and subsequent signaling. The 
C-terminal LRF sequence of KP54 is required to bind KISS1R (Ohtaki et al., 2001). This LRF-
amide binding motif is a common theme shared by the neuropeptide/neuropeptide receptor 
family. Without the LRF motif, KP54 is unable to bind to KISS1R (unpublished data). It was 
found that MMP9 can bind and cleave KISS1 between and Gly118 and Leu119 (Takino et al., 
2003). This cleavage event prevents KP54 from binding KISS1R. Interestingly, it was also 
observed in this study that MMP2 and MMP9 can form a stable binding interaction with KISS1, 
seemingly contingent on KISS1’s Cys53 and cysteine disulfide binding. This binding event was 
stable and seemed to only require association with the N-terminal domain of KISS1 (Takino et 





KISS1R is a Gq/11-protein coupled receptor heavily distributed through the central nervous 
system and reproductive axis (Kotani et al., 2001; Muir et al., 2001; Ohtaki et al., 2001). The 
activation of KISS1R leads to canonical Gq/11 downstream signaling. KISS1R binding induces 
activation of phospholipase C (PLC), the primary effector of this signaling cascade. Activated 
PLC hydrolyzes phosphatidylinositol 4,5-bisphosphate (PIP2), releasing second messengers 
inositol 1,4,5 triphosphate (IP3) and diacylglycerol (DAG). Released IP3 binds receptors on the 
endoplasmic reticulum and causes release of intracellular calcium. Diacylglycerol then activates 
protein kinase C, which activates MAPK signaling through Ras and Raf phosphorylation (Ringel 
et al., 2002). This signaling results in ERK phosphorylation and nuclear translocation, leading to 
a modified transcriptional profile.   
In addition to the normal Gq/11 signaling, the initial characterization of KISS1R yielded additional 
characteristics that could help explain how KISS1 and KISS1R suppress metastasis. Ohtaki 
observed the formation of stress fibers and phosphorylation of FAK, both of which are signs of 
actin cytoskeletal reorganization (Ohtaki et al., 2001). Consistent with this theme, inhibition of 
migration and invasion was observed in a dose-dependent response to KP54 stimulation (Ohtaki 
et al., 2001).  In B16 melanoma cells transfected with KISS1R or blank, administration of KP54 
via osmotic pump suppressed metastasis from the murine footpad only in samples expressing 
KISS1R (Ohtaki et al., 2001). These observations led to the initial conclusion that KISS1R was 
the signaling mechanism through which KISS1 suppressed metastasis.  
When examining the tissue distribution of both KISS1R and KISS1, there was overlap in the 
distribution of KISS1 and KISS1R expression in the neuroendocrine system. Both KISS1 and 
KISS1R are expressed in the brain, pituitary, spinal cord, heart, pancreas, placenta, lymphocytes, 
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spleen, breast, and testes (Kotani et al., 2001; Mead et al., 2007; Muir et al., 2001; Ohtaki et al., 
2001). The highest expression of both KISS1 and KISS1R was found in placenta, suggesting an 
important interaction in both the neuroendocrine system as well as the fetal-maternal interface of 
the placenta. Additionally, this distribution throughout the reproductive system also hinted at a 
physiological function for KISS1: KISS1R signaling outside of metastasis suppression.  
KISS1 and KISS1R as key modulators of puberty and fertility 
While the roles of KISS1 and KISS1R lacked immediate clarity in the field of metastasis 
suppression, the endogenous functions of KISS1 and KISS1R were easier to decipher. The 
normal function of KISS1R was identified through two studies of familial idiopathic 
hypogonadotropic hypogonadism. These studies independently identified deletions in KISS1R 
which truncated the receptor and rendered it unable to signal properly (de Roux et al., 2003; 
Seminara et al., 2003). These studies found that KISS1 and KISS1R were critical for the onset of 
puberty and maintenance of fertility. Additional studies would find that even minor mutations in 
KISS1R were the cause for many causes of idiopathic hypogonadotropic hypogonadism, and that 
the syndrome could be recapitulated in mice with a KISS1R knockout (Seminara et al., 2003). 
Following this discovery, KISS1 and KISS1R were found to be expressed in the hypothalamus in 
an estrous-cycle dependent manner (Navarro et al., 2004). Additionally, stimulating the 
hypothalamus with KP54 stimulated luteinizing hormone (LH) surges, which indicated that 
KISS1 can directly induce gonadotropin releasing hormone (GnRH) release and signaling 
through LH and follicle stimulating hormone (FSH) (Messager et al., 2005; Navarro et al., 2004; 
Navarro et al., 2005). Cumulatively, these studies identified that estrogen negatively regulates 
KISS1 expression in the hypothalamus, and when estrogen drops during the menstrual/estrous 
cycle, KISS1 expression increases, stimulating KISS1R on GnRH neurons, which in turn 
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stimulates release of LH and FSH from the pituitary. This role of KISS1 is critical, and is 
evolutionarily conserved through many higher and lower evolutionary branches (Biran, Ben-Dor, 
& Levavi-Sivan, 2008). These observations in the hypothalamus gave rationale to the high 
expression of KISS1 and KISS1R in the brain and spinal cord.  
While KISS1 and KISS1R have a critical role in the hypothalamic pituitary gonadal axis, KISS1 
has a dual role in the realm of fertility. Circulating blood levels of KISS1 increase by roughly 
900-fold during pregnancy (Horikoshi et al., 2003). Noting that placenta has the highest 
expression of KISS1, this suggested a role for KISS1 and KISS1R at the maternal-fetal interface 
of the placenta (Janneau et al., 2002). Bilban et al. showed that KP10 treatment decreased the 
invasiveness of primary human trophoblasts (Bilban et al., 2004). This study demonstrated that 
KISS1 and KISS1R were differentially expressed throughout the placenta and cooperatively 
function to regulate placental invasion. Immunohistochemistry analysis showed that while 
KISS1 is expressed by syncytiotrophoblasts near the fetal interface of the placenta, KISS1R is 
expressed by the syncytiotrophoblasts as well as the cytotrophoblasts on the maternal side of the 
placenta (Bilban et al., 2004). This expression dynamic appears to be predominantly in first term 
placentas, and can regulate angiogenesis on placental endothelial cells (Matjila, Millar, van der 
Spuy, & Katz, 2013; Ramaesh et al., 2010). Manipulations, particularly lower expression, of the 
KISS1/KISS1R maternal/fetal interface have been reported to be linked to pre-eclampsia and 
repeated loss of pregnancy, again conveying the importance of regulating placental invasion to 
successful pregnancy (Armstrong et al., 2009; Cartwright & Williams, 2012; Park et al., 2012; 
Zhang et al., 2011). As a suppressor of placental invasion, KISS1 in a normal physiological 
function hints at how it suppresses metastasis. 
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Conflicting roles for KISS1R in metastasis suppression 
The initial characterization of metastin and KISS1R activation in metastasis suppression by 
Kotani, Muir, and Ohtaki did not definitively define the signaling which was responsible for 
metastasis suppression. The study by Ohtaki et al. found that KISS1R activation suppressed 
migration and invasion, which they attributed to the formation of stress fibers and 
phosphorylated FAK (Ohtaki et al., 2001). Additional studies struggled to find a common 
mechanism of metastasis suppression in additional models. In MDA-MB-435S cells, Becker et 
al. found that stimulation of KISS1R resulted in cell cycle arrest and increased rates of apoptosis 
(Becker et al., 2005). This observation was echoed in a study of human pituitary adenomas 
which overexpress KISS1 and KISS1R, where an increase in apoptotic rate was seen foll3owing 
treatment with KISS1 (Martinez-Fuentes et al., 2011). These observations appear to be specific 
to their individual models, however. A study in human fibroblasts suggested that KISS1 
expression decreased NFκB nuclear translocation, resulting in decreased expression of MMP9 
(Yan, Wang, & Boyd, 2001). Other studies in HUVEC (human umbilical endothelial) cells found 
that KP10 stimulation decreased expression of VEGF through inhibition of SP-1 binding to its 
promoter (Cho et al., 2009). A series of studies investigated the interactions with KISS1R and 
the chemokine receptor CXCR4, the receptor for the chemokine SDF-1 (Navenot, Wang, 
Chopin, Fujii, & Peiper, 2005). These studies claimed that KP10 treatment to cells co-expressing 
KISS1R and CXCR4 desensitized them to SDF-1 treatment, resulting in a suppression in 
invasion and migration (Navenot et al., 2005). The group then claimed that KISS1R stimulation 
could abrogate CXCR4/SDF-1 signaling through MAPK and Akt to inhibit pro-metastatic 
signaling (Navenot, Fujii, & Peiper, 2009). Cumulatively, while there is evidence that KISS1R 
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signaling can result in metastasis suppressing phenotypes, its role in metastasis suppression is not 
well understood. 
The mechanism by which KISS1 and KISS1R suppress metastasis continues to increase in 
complexity in the case of breast cancer. While KISS1 is a broad-reaching metastasis suppressor 
in several cancer types, its role in breast cancer is less straightforward. This complexity in breast 
cancer seems to be related to the presence or absence of ERα. Lymph node positive cases of 
breast cancer demonstrated higher levels of KISS1 mRNA as compared to lymph node negative 
tumors from a 2003 study (Martin, Watkins, & Jiang, 2005).  A study in ER-positive breast 
cancer patients found that while ER-positive tumors had less KISS1 expression than ER-negative 
tumors, and that in vitro re-introduction of ERα into ER-negative cells subsequently decreased 
KISS1 expression (Marot et al., 2007). The same study found that patients with ER-positive 
tumors with high KISS1 expression had significantly lower relapse-free survival than ER-
positive patients with low KISS1 expression, suggesting that the feedback loop from ERα to 
suppress KISS1 expression could be disrupted with tumor progression (Marot et al., 2007). 
While this study was unable to observe statistically significant KISS1R disease data, others 
followed which suggested that KISS1R may have a role to play in promoting breast cancer 
metastasis. In a mouse mammary tumor virus–polyoma virus middle T antigen (MMTV-PyMT) 
model, Cho et al. developed a KISS1R heterozygous sub-strain to investigate the impact that 
KISS1R heterozygosity had on tumor progression and metastasis in this highly aggressive model 
of breast cancer (Cho et al., 2011). This study found that by depleting either KISS1 or KISS1R 
expression in breast epithelium delayed tumor latency, tumorigenesis, and metastasis (Cho et al., 
2011). This study was pivotal in demonstrating the immediate impact that KISS1 and KISS1R 
signaling has on breast hyperplasia and tumor progression. A possible mechanism by which 
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KISS1/KISS1R promote tumorigenicity and metastasis was addressed in a report by Zajac et al., 
which found that KISS1R could trans-activate EGFR, a receptor tyrosine kinase with a notorious 
role as a tumor-promoting receptor (Zajac et al., 2011). This study directly identified the ability 
of KISS1R to bind and activate EGFR, but the effect appears to be dependent on a lack of ER 
expression (Cvetkovic et al., 2013). This observation could explain the increased invasiveness, 
migration, and metastasis observed in many KISS1/KISS1R positive breast cancers. Overall, 
there is a slowly growing body of work implying that KISS1 and KISS1R are heavily regulated 
by ERα and that their role in breast cancer is not a one of simple metastasis suppression.  
Interestingly, the conflicted role of KISS1 and KISS1R in metastasis suppression goes deeper 
than model-specific signaling differences. A series of studies have demonstrated that KISS1 can 
suppress metastasis in cells which lack co-expression of KISS1R (Nash et al., 2007). Indeed, the 
initial studies characterizing KISS1 as a metastasis suppressor in human C8161.9 melanoma 
cells were done in lieu of KISS1R expression (Lee et al., 1996; Nash et al., 2007). The 
observation that of NFκB activation and MMP-9 expression was mediated without exogenous 
KISS1R expression or detection in HT-1080 fibroblast cells (Yan et al., 2001). Later, Liu et al. 
discovered that KISS1 expression resulted in a metabolic shift from a glycolytic, Warburg 
metabolism, towards a reliance on oxidative phosphorylation (W. Liu et al., 2014). The 
connection between aggressive tumors and Warburg metabolism has been inferred through the 
field of hypoxia (Denko et al., 2003). Hypoxia signaling can promote the transcription of 
glycolytic genes such as glucose transporters 1 and 3, phosphoglycerate kinase, 6-phosphofructo-
2 kinase, and lactate dehydrogenases A and B (Denko et al., 2003; Ebert, Firth, & Ratcliffe, 
1995; O'Rourke, Pugh, Bartlett, & Ratcliffe, 1996; Salceda, Beck, & Caro, 1996; Semenza et al., 
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1994). Since the cores of even small tumors can quickly become hypoxic, it is not surprising that 
hypoxia plays such a driving force in metabolism and tumor progression.  
Warburg metabolism was first described by Otto Warburg as the preference of tumor cells to 
utilize glucose as a primary metabolic substrate (Warburg, Wind, & Negelein, 1927). The 
preferential utilization of glucose and glycolysis by tumors has since been referred to as Warburg 
metabolism. By relying heavily on glycolysis, glycolytic intermediates can be used towards 
generation of nucleosides and amino acids (Potter, 1958; Vander Heiden, Cantley, & Thompson, 
2009). In fact, the reliance of cancer cells on the Warburg effect is so widespread that it is now 
considered one of the hallmarks of cancer (Hanahan & Weinberg, 2011). This form of energy 
metabolism is not unheard of in normal tissues. Normal tissues can quickly stabilize HIF1a to 
primarily utilize glycolysis as an energy producing avenue in times of ischemia or acute hypoxia. 
Activated T-cells switch from beta-oxidation of fatty acids to a glycolytic metabolism during 
activation and outgrowth to enrich for biosynthetic glycolytic by-products (Gerriets & Rathmell, 
2012). The transition to a glycolytic metabolism provides cancer cells with the molecular 
components for unchecked division.  
The observation that KISS1 expression seemed to reverse the Warburg effect in cancer cells 
provided a possible explanation for how KISS1 suppresses metastasis independent of KISS1R 
signaling. In addition to suppressing glycolytic metabolism and increasing oxygen consumption, 
KISS1 expression was also noted to increase mitochondrial mass and function (W. Liu et al., 
2014). This observation was traced backwards to the stabilization of a transcription factor, 
Pgc1α, in the presence of KISS1. Peroxisome proliferator-activated receptor gamma coactivator 
(Pgc1α) is a transcription co-activator which can bind with transcriptional co-activators to 
promote transcription of metabolism-related genes. While the two proteins did not physically 
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associate, KISS1 expression appeared to stabilize Pgc1α protein and allowed it to promote a 
transcriptional program associated with oxidative phosphorylation. KISS1’s impact on cellular 
metabolism suggests that KISS1 may interfere with cellular energy sensing mechanisms, a 
phenotype unrelated to KISS1R signaling.  
More recent observations of KISS1 suppressing metastasis in lieu of KISS1R expression give 
rise to several questions. Namely, if KISS1R co-expression is not required for metastasis 
suppression, then how does KISS1 suppress metastasis? As a secreted peptide, KISS1 has the 
potential to act in an autocrine, juxtacrine, or paracrine manner. In the hypothalamus and the 
pituitary, KISS1 is secreted from KISS1 neurons to stimulate KISS1R on GnRH neurons 
(Messager et al., 2005). This extracellular activity in the hypothalamus and pituitary could easily 
be recapitulated elsewhere in the body. Low levels of KISS1R mRNA have been detected in 
several metastatic sites (e.g. lung, liver, brain), but no studies have been done to determine 
whether KISS1R expression in the stroma is sufficient for KISS1 to suppress metastasis (Kotani 
et al., 2001; Muir et al., 2001; Ohtaki et al., 2001). While KISS1 and KISS1R co-expression can 
result in inhibition of metastatic traits in vitro (such as suppression of proliferation, migration, 
and invasion), these phenotypes have also been demonstrated without KISS1R co-expression 
(Lee & Welch, 1997b; Shoji et al., 2009). Additionally, the metabolic phenotype induced by 
KISS1 expression was observed without co-expression of KISS1R (W. Liu et al., 2014). This 
gap in knowledge, presents the hypothesis that KISS1 can suppress metastasis through a non-
KISS1R pathway. 
Within the neuropeptide family, there is an established precedent for ligands signaling through 
alternate receptors (Lyubimov et al., 2010; Oishi et al., 2011). Neuropeptide receptors share an 
affinity for ligands with a C-terminal RF-amide motif (Walker, 1992). Within this family, there 
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exists variation in the specific receptors and ligands, but this preference for RF-amide as a 
binding site suggests a degree of promiscuity exists amongst ligands and receptors. This is true in 
the case of KISS1 and NPFF (neuropeptide FF), an 8-amino acid neuropeptide signaling 
molecule sharing a high degree of structural similarity with KP10 (Milton, 2012). KISS1, more 
specifically KP10, can activate NPFFR1 and 2 (neuropeptide FF receptors) with a high degree of 
affinity (Lyubimov et al., 2010; Oishi et al., 2011). This cross-reactivity between kisspeptins and 
neuropeptide receptors demonstrates the possibility that once outside of the cell, KISS1 may 
have a more complicated role to play in metastasis suppression than simply signaling through 
KISS1R.  
While KISS1’s ability to bind to neuropeptide receptors 1 and 2 has been described in the 
literature, most studies focus exclusively on the KP54 or KP10 domain of KISS1. Indeed, once it 
was discovered that KP54 was a receptor ligand in 2001, few groups have studied KISS1 as a 
metastasis suppressor without co-expression of KISS1R in their model system. In addition to 
this, the remaining peptide fragments of KISS1 have never been thoroughly investigated after 
characterization of KP54. Additionally, KISS1 processing outside of the cell releases not only 
KP54, but also all other kisspeptin fragments achieved by furin cleavage (Harihar et al., 2014). 
The extracellular nature of KISS1 processing presents the possibility that non-KP54 kisspeptins 
could bind and activate alternate receptors. By neglecting to study the rest of the protein, the 
field neglects the possibility that the metastasis suppressing capabilities of KISS1 could be 
resultant of more than KP54 and KISS1R signaling.  
We hypothesize that non-K54 kisspeptins will possess anti-metastatic activity. In this study, we 
examined each theoretical cleavage product of KISS1 to systematically define the metastasis 
suppressing characteristics of each kisspeptin. Our results provide evidence that KP54 is not the 
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only domain of KISS1 necessary for metastasis suppression. These findings bring new direction 
to the field of KISS1 metastasis suppression and support the further research of non-KP54 
kisspeptins Taken together, these data support the further study of the N-terminal domain of 




















 Metastasis suppressors are a family of protein and RNA which, when expressed by a 
tumor, allow for primary tumor growth but prevent successful metastasis by inhibiting one or 
more stages of the metastatic cascade (Steeg et al., 2003). One member of this family, KISS1, is 
a secreted protein which inhibits metastasis at the colonization stage of metastasis (Lee et al., 
1996; Lee & Welch, 1997b). KISS1 is a broadly functional metastasis suppressor which 
suppresses metastasis in several tumor types, including breast, melanoma, ovarian, colorectal, 
bladder, esophageal, thyroid, gastric, pancreatic, and endometrial cancers (Beck & Welch, 2010). 
When KISS1 is secreted outside of the cell it is cleaved by furin at three R/K-XX-R/K dibasic 
motifs to yield “kisspeptins,” or smaller KISS1 peptides (Harihar et al., 2014). KISS1 can only 
suppress metastasis if it is secreted outside of the cell, providing evidence that it may have 
potential as a therapeutic peptide to maintain disseminated metastases at a dormant stage (Nash 
et al., 2007; Nash & Welch, 2006).  
 One kisspeptin derived from an internal domain of KISS1 is KP54 (formerly “metastin”), 
a 54-amino acid peptide which binds and activates KISS1R (AKA GPR54, AXOR12, and 
hO7T175). KISS1R is a Gq/11-protein coupled receptor expressed primarily in the hypothalamic-
pituitary-gonadal axis (Kotani et al., 2001; Muir et al., 2001; Ohtaki et al., 2001). KISS1R 
activation induces the formation of focal adhesions, suppression of motility, cell cycle arrest, 
intracellular calcium mobilization, and suppression of MMP-9 expression (Becker et al., 2005; 
Cho et al., 2009; Ohtaki et al., 2001; Yan et al., 2001). Receptor binding is widely considered to 
be the mechanism of action for KISS1 metastasis suppression (J. F. Harms, Welch, & Miele, 
2003; Ohtaki et al., 2001). However, recent studies have found that KISS1 can suppress 
metastasis and metastatic traits in KISS1R-deficient cells (W. Liu et al., 2014; Nash et al., 2007; 
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Wang, Qiao, Wang, & Zhou, 2016). Indeed, a recent study indicated that KISS1 expression can 
reverse the Warburg Effect by means of PGC1α stabilization in cells lacking KISS1R expression 
(W. Liu et al., 2014). This metabolic phenotype was not achieved when cells were treated with 
KP10 exogenously, suggesting that the mechanism by which KISS1 alters tumor cell metabolism 
and metastatic potential is independent of KISS1R interactions. Thus, an alternate hypothesis 
exists: the extracellular cleavage of KISS1 liberates a non-KP54 kisspeptin responsible for 
metastasis suppression independent of KISS1R, potentially through an alternative receptor. To 
test this hypothesis, however, all possible kisspeptin cleavage products must be examined to 
identify the region(s) of metastasis suppression.  
To examine the metastasis suppressing capacities of kisspeptins resultant of furin 
processing, all ten theoretical kisspeptins were generated based on known dibasic cleavage sites. 
These constructs are referred to as the “KISS1 Manufactured Peptides,” or KMPs. These KMPs 
were then cloned into lentiviral vectors and used to generate stable cell lines in B16-F10 murine 
melanoma model. Using the KMPs, we evaluated the metastasis suppression capabilities of each 
individual kisspeptin. Using this system as a tool, we have identified non-KP54 kisspeptins with 
the ability to suppress metastasis. Specifically, the N-terminal domain of KISS1 (M1–K57 or 
KMP2), suppresses metastasis independent of the rest of the protein. These findings indicate that 
the N-terminal domain of KISS1 has anti-metastatic bioactivity. 
Methods and materials 
Cell lines and culture 
B16F10 is a melanotic melanoma cell line derived from a C57BL/6J mouse. These cells 
were cultured and injected into mice ten times to derive their name and enhanced metastatic 
characteristics (Fidler, 1973). Cell lines were cultured in a 1:1 ratio of Dulbecco’s-modified 
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minimum Eagle Media and Ham’s F12 media with 5% fetal bovine serum, 1% l-glutamine and 
0.025% non-essential amino acids. Lentiviral clones were made using Life Technologies 
Gateway platform and then introduced into the B16F10 cell line. The transduced cells were 
cultured in the presence of 4 μG/mL blasticidin (pLenti6-V5-DEST, Invitrogen) or 2.5 μG/mL 
puromycin (pLenti PGK Puro DEST plasmid Addgene #w529-2). A parental B16-F10 control 
cell line was cultured in the same conditions without selection.   
Lentiviral constructs and lentiviral cell line generation 
KMP constructs were designed using a Kozak sequence to initiate translation and flanked 
by BamH1 (5’) and Xho1 (3’) restriction sites. These constructs were ligated into pENTR1A 
dual selection vector (A10462) to allow for recombination into lentiviral vectors. Lentiviral 
vectors used in this study were pLenti6-V5-DEST (V49610, Invitrogen) and pLenti PGK Puro 
DEST (Addgene #w529-2). After recombination into lentiviral vectors, plasmids were sequenced 
and used to make virus in 293FT cells (ThermoFisher Scientific, R70007). Briefly, 3uG of 
lentiviral expression vector was co-transfected with 9uG viral packaging plasmid mix via 
Lipofectamine 2000. 293FT cells were transfected and incubated overnight. Media was changed 
to fresh, complete media and incubated for an additional 24 hours. Viral supernatant was 
aspirated, centrifuged, and immediately used to transduce B16-F10 cells to determine viral titer. 
Selection media was applied 24 hours later and cells were maintained under selection until 
control cells with no virus had completely died. Using viral titer, B16-F10 cells were transduced, 
selected, and colonies were isolated. Expression was tested using RT-QPCR or western blot.  
Experimental metastasis assays and animal studies 
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Cells were disassociated and suspended in ice-cold Hank’s Buffered Saline Solution. For 
injection, 200 μL of cell suspension (1.0 x 104 or 5.0 x 104 cells) was injected into the lateral tail 
vein of 4-week-old female syngeneic C57BL/6J mice (10 per sub-clone, three sub-clones per 
KMP; C57BL/6J Jackson Laboratories). Mice were housed at 23̊ºC and given food and water ad 
libitum for two weeks. Upon euthanasia, gross lung metastases were quantified by light 
microscopy under a dissection microscope. 
Statistics  
Statistical tests were conducted via One Way ANOVA followed by pair-wise post-tests 
(Shapiro-Wilk normality test, Dunn’s Method pairwise multiple pairwise comparison 
procedures) for experimental groups containing more than two treatment groups. 
Immunofluorescence and phalloidin staining 
To perform actin staining, cells were plated at 5x103 cells per well and left to incubate 
overnight. Once cells had reached roughly 50% confluence, wells were washed twice with PBS 
then fixed with 3.7% paraformaldehyde for 10 minutes. The wells were washed twice more, then 
cells were extracted with 0.1% PBS-Triton 100 for 5 minutes. Wells were washed twice more, 
then stained with diluted phalloidin stain in 200 μL PBS for 20 minutes. Following this, wells 
were washed twice more before mounting coverslips using VectaShield with DAPI. Slides were 
left at 4ºC in the dark to dry before fluorescent imaging.  
Anoikis resistance and clonogenicity assays 
Cells were plated at 2.5x105 cells per dish in 60mm low attachment dishes. Cells were 
cultured under normal conditions for 4 days before scraping and triturating cells for counting 
using a hemacytometer. Trypan blue exclusion was used to assess viability following culture in 
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low attachment plates. Cells were subsequently plated at 1x103 live cells in triplicate in a 6-well 
dish. Cells were left to form colonies for 4 days. Colonies were fixed in 0.01% crystal violet and 
colonies were counted using ImageJ 
Metabolic studies and flow cytometry 
To measure mitochondrial function, B16F10 cells (2 x 104) were seeded onto a Seahorse 
Bioanalyzer XF plate and O2 consumption was measured sequentially following addition of 
electron transport chain inhibitors oligomycin (inhibitor of complex IV, ATP synthase), carbonyl 
cyanide 4-(trifluoromethoxy) phenylhydrazone (FCCP; mitochondrial uncoupler), rotenone 
(complex I inhibitor), and antimycin A (complex III inhibitor). For flow cytometry analysis, cells 
were harvested, counted, and suspended to a total concentration of 1x106 cells per mL in warm 
PBS. Cells were permeablized for 15 minutes at 37ºC and then stained with 200nM Mitotracker 
Red CMXRos or Mitotracker Green FM for 30 minutes in the dark at room temperature. Cells 
were then analyzed with flow cytometry for median fluorescence intensity.  
Wound healing assay 
Cells were grown to confluence in a 6-well dish. Using a 200 µl pipette tip, a scratch was 
introduced into the field in triplicate. The wells were washed twice with PBS to remove debris 
and were then incubated in serum-free media until imaging at 18 hours to assess migration. 
Migration was quantified using ImageJ by three measurements averaged over the distance of the 
scratch.  
Melanosphere formation 
To assess the impact of kisspeptin expression on stemness and spheroid formation, a 
melanosphere formation assay was performed. In a protocol adapted from (Le Coz et al., 2016), 
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1x103 cells were plated in each well of a 24 well ultra-low attachment plate (Corning) in serum-
free DMEM F:12 containing 1X B27 (ThermoFisher Scientific), 20ng/ml murine EGF 
(Peprotech), and 20 ng/ml murine bFGF (Peprotech). Cells were left to incubate for 10 days 
before counting and imaging using the Celigo Imaging System.  
RT-QPCR 
RNA was harvested from cells with Zymogen’s QuickRNA Prep Kit and was 
subsequently reverse transcribed into cDNA using iScript cDNA kit (BioRad). Expression was 
then tested using SYBR Green PCR reagent and primers specific to each KMP (table). Results 
were analyzed using comparative Ct values and delta Ct values. 18S was used as an internal 
control. Three KMP clones with the highest expression were chosen for in vivo experimentation. 
FLAG ELISA 
FLAG ELISA was performed as a method to validate the presence of FLAG-tagged KMP 
constructs. To do this, the DYKDDDDK (flag) tag ELISA Kit (Advanced Bioscience Reagents) 
was used per the manufacturers protocol. Briefly, 250 µg whole cell lysates were applied to a 
pre-warmed ELISA plate and incubated at 37C for 2 hours. Three washes were performed, 
followed by incubation with a detection antibody for 1 hour at room temperature. The plate was 
washed and TMB solution was applied, followed by stop solution. The plate was read using a 
plate reader and absorbance at 450nm was recorded. Values were normalized to a standard curve. 
Results 
Kisspeptin design and detection 
To test the metastasis suppressor capabilities of different KISS1 domains, all ten theoretical 
kisspeptins were designed and cloned into the Invitrogen Gateway system. As antibodies to 
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KISS1 recognize only the KP54 region of KISS1, a FLAG tag was introduced to each of these 
constructs (depicted with gray diagonal lines). Kisspeptins lacking the N-terminal domain of 
KISS1 were cloned to contain KISS1’s 19-amino acid secretion sequence (black diagonal lines). 
These kisspeptins recapitulate the results of normal KISS1 processing by furin without 
confounding results from other KISS1 fragments in the extracellular environment. B16-F10 






















































































































































Figure 1: A, Diagram of kisspeptin construction and design. Black diagonal boxes 
denote KISS1’s 19-amino acid secretion sequence. Red diagonal lines depict FLAG tag 
(DYKDDDDK). B, RT-QPCR analysis of KMP expression.     
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analysis or western blot (not pictured) (Figure 1B). Three clones with the highest expression 
were selected for experimental use in subsequent studies. 
Kisspeptins differentially suppress metastasis in vivo 
To test the ability of kisspeptins to suppress metastasis, an experimental metastasis assay 
was performed in syngeneic C57Bl6/J mice. The experimental metastasis assay evaluates 
metastatic efficacy by recapitulating the latter half of the metastatic cascade. As KISS1 functions 
at the final step, colonization, of metastasis, this experiment allows for evaluation of KISS1 and 
kisspeptin impact on metastasis suppression. Metastatic load in the lungs was quantified 
following injection of three cell line clones per kisspeptin (n=10 mice per clone, n=30 mice per 
kisspeptin). While full-length KISS1 suppresses metastasis and parental B16F10 cells did not, 
kisspeptins displayed variable extents of metastasis suppression (Figure 2). Interestingly, KMP6 
(KP54) suppressed metastasis despite a lack of KISS1R expression in B16-F10 cells. This 
observation suggests that KP54 may be able to suppress metastasis by activating stromal 
KISS1R.  
Kisspeptins which included the N-terminal domain of KISS1 and/or KP54 tended to 
suppress metastasis (KMP2, KMP3, KMP4, p<0.05 One way ANOVA). Kisspeptins which 
contain the C-terminal domain of KISS1 tended to not suppress metastasis (KMP8, KMP10). 
Overall, these results suggest that both the KP54 domain of KISS1 as well as the N-terminal 
domain of KISS1 (KMP2) have metastasis suppressor capabilities. The metastasis suppressor 
capabilities of KP54 appear to be negated by the presence of the C-terminal domain of KISS1 
(KMP10). To validate the results for clones which demonstrated intra-clonal variation, an 




Figure 2: Experimental metastasis of KMP 1 
* 



























B16F10 KISS1 2 3 











Figure 2: A, Bar graph representation of lung metastases following experimental 
metastasis assay. Each KMP cell line is the average number of metastases of three KMP 
sub-clones (n=30). Red asterisks denote KMP which are statistically similar to B16-F10 
parental control by one way ANOVA analysis (p<0.05). B, Representative lung photos 































Figure 3: Bar graph representation of a repeated experimental metastasis assay of KMP 




). Red asterisks denote 
groups which are statistically similar to B16-F10 group (P>0.05, One way ANOVA 
followed by Dunn’s Method pairwise comparison).   
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cells). At a 5X increase in cell number, KMP2 continued to suppress metastasis (Figure 
3). Other kisspeptins demonstrated variable metastasis suppressor capabilities at an increased cell 
density. 
At an increased cell density, KMP5 no longer suppressed metastasis. KMP8 continued to 
not suppress metastasis compared to parental controls. KMP10 suppressed metastasis at a higher 
injection density. While some kisspeptins demonstrated variable metastasis suppression abilities, 
KMP2 continued to completely suppress metastasis in every clone (n=15 per KMP cell line).   
These data demonstrate that not all kisspeptins suppress metastasis equally. KP54 appears 
to be sufficient for metastasis suppression despite a lack of KISS1R co-expression. Interestingly, 
the N-terminal domain of KISS1, KMP2, also can suppress metastasis in an apparently KISS1R 
independent manner. For the remainder of these studies, the metastasis suppressor phenotype of 
KMP2 has been investigated.  
Proliferation is not depressed by kisspeptins 
One hypothesis to explain differential metastasis suppression by kisspeptins is 
suppression of proliferation. To test the impact of kisspeptin expression on proliferation, a 
proliferation assay was performed in three sub-clones of each kisspeptin (Figure 4). Clonal 
variation in growth was observed within each set of sub-clones. However, after five days of 
growth, no significant changes in proliferation were assessed between suppressor and non-
suppressor kisspeptins. This leaves the conclusion that a modulation of proliferation is not likely 






Figure 4: Proliferation of KMP 1  
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Figure 4: Log-transformed growth curve of KMP expressing cell lines to examine growth 
rates of kisspeptin-expressing cells. While variation exists in growth rates between KMP 
expressing cell lines, suppressor kisspeptins do not uniformly suppress proliferative rates. 
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Cell cycle distribution and is not impacted by KMP expression 
The expression of suppressor kisspeptins does not lead to a uniform suppression of 
proliferation. However, one mechanism of metastatic dormancy is cell cycle arrest at a secondary 
tissue. To evaluate cell cycle distribution with expression of kisspeptins, flow cytometry with 
propidium iodide was performed on parental B16-F10, KISS1-, KMP2, KMP6/KP54, and KMP8 
expressing cell lines. These kisspeptins were selected to analyze effects of suppressor and non-
suppressor kisspeptins on cell cycle distribution in comparison to KISS1 and parental controls. 
The expression of KISS1 did not induce any significant changes in cell cycle distribution as 
compared to parental control (Figure 5A). Cells expressing suppressor kisspeptin KMP2 contain 
a lower population of cells in both G0/G1 and S phases, yet a comparable population of G2/M 
phase cells (Figure 5B). KMP6 expression led to a slight enrichment in G2/M phase (Figure 5C). 
Non-suppressor KMP8 exhibited a larger population of cells in G0/G1 and G2/M phases than 
parental controls, suggesting an increased tendency towards proliferation with the expression of 
this kisspeptin (Figure 5D). These data suggest cumulatively that cells which express non-
suppressor kisspeptins may have a slight tendency towards active cellular division compared to 
cells expressing suppressor kisspeptins.  
Suppressor kisspeptins inhibit migration in vitro 
A classic characteristic of metastatic cells is their ability to migrate and invade into 
surrounding tissues. In a screen of all kisspeptin-expressing lines, a wound healing assay was 
conducted to observe the impact of kisspeptin expression on in vitro migration. After introducing 
a scratch into a confluent field of cells, migration was evaluated over an 18-hour timeframe. 












Figure 5: Cell cycle analysis of B16-F10 parental vs. KISS1 or kisspeptin expressing 
cells through propidium iodide staining. Black lines denote B16-F10 parental controls, 
colored lines correspond to KISS1 or kisspeptin expressing cell lines. A, B16F10 vs KISS1 




Figure 6: KMP suppress migration 1  
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Figure 6: Wound healing assay of B16-F10, KISS1, and kisspeptin expressing  cell lines. 
White dotted lines denote migration borders at T=0 hours and T=18 hours. Kisspeptins 








































































Figure 7: Quantification of wound closure at T=18 hours of migration. Two clones per 
kisspeptin-expressing line and three images per clone were evaluated. 
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6, Figure 7). Expression of KMP7, KMP8, KMP9, and KMP10 did not suppress 
migration. The kisspeptin cell lines which suppressed migration tended to include the N-terminal 
and/or KP54 domain of KISS1. Additionally, the kisspeptins which did not suppress migration 
(KMP7, 8, 9, and 10) tended to contain the KP54 domain of KISS1 and/or the C-terminal 
domain of KISS1. The trend of migration suppression tended to correlate with in vivo metastasis 
suppression. Cumulatively, kisspeptins which suppress migration in vitro tend to suppress 
metastasis in vivo.  
Mitochondrial mass and function is elevated by KMP2, KISS1 expression 
 Liu et al. reported that the expression of KISS1 elevates mitochondrial mass and 
oxidative phosphorylation, potentially through stabilization of PGC1α and increased 
mitochondrial biogenesis (W. Liu et al., 2014). To test whether suppressor kisspeptin expression 
results in similarly elevated mitochondrial mass, cells were stained with Mitotracker Red FM or 
Mitotracker Green. Mitotracker Red staining selectively stains for mitochondria with an active 
mitochondrial membrane potential, while Mitotracker Green stains for total mitochondrial mass. 
Mitotracker Green staining demonstrated that total mitochondrial load has little variation 
between parental B16-F10, KISS1, KMP2, and KMP6/KP54 (Figure 8A). Interestingly, KMP8-
expressing cells presented an increase in mitochondrial mass (1.9 fold higher than parental 
control). However, Mitotracker Red staining demonstrated that KISS1 expression elevated 
functional mitochondrial mass 1.64-fold compared to B16-F10 parental cells (Figure 8B). 
Expression of KMP2 was sufficient to elevate functional mitochondrial mass 1.87-fold compared 
to parental controls. Expression of KMP6/KP54 did not increase mitochondrial mass, and indeed 












































































Figure 8: A, Flow cytometry analysis of B16-F10 and KMP expressing lines with 
Mitotracker Green staining for total mitochondrial load. Values relative to B16-F10 
parental controls. B, Flow cytometry analysis of Mitotracker Red staining of B16-F10 and 
kisspeptin expressing cell lines for mitochondria with active membrane potential. Values 






































































































Figure 9: A, Seahorse Bioanalyzer X7 oxygen consumption rate (OCR) for B16F10 
(black), B16-F10 KISS1 (green), B16-F10 KMP2 (red) normalized to protein content. B, 
Basal oxygen consumption calculated from oxygen consumption rate. Expression of KISS1 
and KMP2 both increase B16-F10 basal oxygen consumption compared to parental control 
(diagonal lines). C, Maximum respiration for both KISS1- and KMP2-expressing cell lines 
is elevated compared to parental control. D, ATP-linked respiration calculated from OCR 
is increased in both KISS1- and KMP2- expressing cell lines compared to parental control.  
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functional mitochondrial biomass (1.39 fold). These data show that the expression of 
kisspeptins variably alters functional mitochondrial load without largely impacting total 
mitochondrial mass. Additionally, the increase in functional mitochondrial mass was induced by 
KMP2, which lacks the KISS1R binding motif. Therefore, this effect does not appear to be 
resultant of KISS1R stimulation. 
To further investigate the similarities between KISS1 and KMP2’s impact on 
mitochondrial function, oxygen consumption rate was examined using a Seahorse BioAnalyzer 
MitoStress Test. Overall normalized oxygen consumption levels were elevated in both KISS1 
and KMP2 cell lines (Figure 9A). When testing for basal oxygen consumption, both KISS1 and 
KMP2 elevated basal oxygen consumption levels (Figure 9B). Additionally, KISS1 and KMP2 
both elevated ATP-linked respiration compared to parental control (Figure 9C). Maximum 
respiration was elevated with both KISS1 and KMP2 expression as well (Figure 9D). 
Cumulatively, these data confirm that the expression of KISS1 elevates functional mitochondrial 
mass. This phenotype is consistent with KMP2 expression, suggesting that KMP2 could be the 
kisspeptin which is responsible for the metabolic phenotype observed with KISS1 expression. 
Resistance to anoikis and clonogenicity is altered by KMP2 expression 
 A key metastatic trait is the ability to resist anoikis, or programmed cell death due 
to lack of adhesion to other cells or a basement membrane (Yawata et al., 1998). To test if 
suppressor kisspeptin expression induces a sensitivity to anoikis and results in inhibited 
colonization, cells were cultured under low attachment conditions for 96 hours before assessing 
viability by trypan blue exclusion. Parental control cells were 59% viable after low attachment 





Figure 10: Anoikis and clonogenicity 1  
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Figure 10: A, Cell viability by trypan blue exclusion was measured after 96 hours under 
low attachment conditions. Cells expressing KMP2 have a higher viability than those 
expressing KISS1, KMP6, or KMP8. B, 1x10
4
 viable cells were re-plated and allowed to 
form colonies to evaluate clonogenicity following culture under low attachment conditions. 
Despite having the highest viability following low attachment, KMP2-expressing cells have 
the lowest clonogenicity.   
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expressing cells were at 53%, suggesting no large change following KISS1 expression 
(Figure 10A). KMP6/KP54 cell viability was depressed to 40%, and non-suppressor KMP8 
viability was at 25%. Surprisingly, KMP2 expression elevated cell viability to 82%. These data 
suggest that suppressor KMP do not result in decreased viability following low attachment 
conditions. 
Following 96 hours in low attachment conditions, 1x104 viable cells were plated in tissue 
culture plates and a clonogenic assay was conducted for 96 additional hours. B16-F10 parental 
controls formed roughly 55 colonies on average, and KISS1 expressing cells formed 62 (Figure 
10B). KMP6/KP54 expressing cells formed 60 colonies on average, and KMP8 cells formed 38. 
KMP2 expressing cells formed 30 colonies. There was little change with KISS1 or KMP6/KP54 
expression on anoikis resistance or clonogenicity. KMP8, a non-suppressor kisspeptin, 
demonstrated low viability in low attachment and a consequently low clonogenicity. Expression 
of KMP2 resulted in higher viability following low attachment conditions, indicating a resistance 
to anoikis, yet lower clonogenicity. 
Actin cytoskeletal organization is not modulated by KMP expression 
One of the notable phenotypes induced by KISS1R stimulation is the formation of stress 
fibers and focal adhesions (Ohtaki et al., 2001). To examine the impact of kisspeptin expression 
on actin cytoskeletal dynamics, phalloidin staining was performed. No changes in dendritic 
projections, cellular morphology, or stress fiber formation was observed between kisspeptin 
expressing cell lines and KISS1 (Figure 11). The expression of KISS1R in B16-F10 parental 
cells is undetectably low. Together, these data suggest that KMP2 expression has no discernable 
impact on cytoskeletal organization. 
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KMP2-3XFLAG protein is detectable by ELISA and suppresses metastasis 
 The metastasis suppressor characteristics demonstrated by KMP2 have been 
characterized using a construct tagged with a single FLAG tag (DYKDDDDK). However, the 
small molecular weight of KMP2 (estimated 7.02 kDa) results in a challenge to identify by 
western blot. To verify protein abundance of KMP2, a 3X-FLAG tag was introduced to the C-
terminal domain of KMP2 to replace the single FLAG tag. This construct was used to generate 
new lentiviral cell lines in B16-F10. To test for expression and abundance of KMP2-3XFLAG, a 
FLAG ELISA was performed (Figure 12A). The three highest expressing KMP2-3XFLAG cell 
lines (clones 2, 3, and 4) were selected for an experimental metastasis assay to verify that the 
introduction of the 3X-FLAG tag did not interfere with metastasis suppression (Figure 12B). 
This experiment confirmed that the introduction of 3X-FLAG tag increases the detection of 






Figure 11  





Figure 11: Phalloidin staining for actin networks demonstrates no large 
cytoskeletal reorganizations following kisspeptin or KISS1 expression in B16-


















































































































































































































Figure 12: A, KMP2-3XFLAG constructs are readily detectable by FLAG ELISA. The 
top three expressing clones (clones 2, 3, and 4) were chosen for  use in  experimental 
metastasis assay.  B, KMP2-3XFLAG-expressing cells suppress metastasis in vivo 
compared to parental control.  
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KMP2 expression inhibits melanosphere formation 
A strong indicator of stemness and propensity to metastasis is the ability for cancer cells 
to form spheroids. The ability of melanoma cells to form spheroids, called melanospheres, has 
been noted as an indicator of invasive and metastatic potential. To test the ability of KISS1 and 
kisspeptins to inhibit melanosphere formation, a melanosphere assay was performed using ultra 
low attachment plates. Cells were cultured for 10 days before imaging and analysis. Both number 
of melanospheres and abundance of cells remaining were evaluated. Compared to control, KISS1 
had no large impact on melanosphere formation (Figure 12). Expression of KMP6 or KP54 did 
not inhibit melanosphere formation. However, KMP2-expressing cells formed 10-fold fewer 
spheroids. These data suggest that the expression of KMP2, in lieu of the remaining KISS1 
protein, inhibits melanosphere formation and melanoma stem-like characteristics. This 
observation supports the other data that KMP2 suppresses metastasis through a mechanism 
independent of KP54 and KISS1R expression. 
Conclusions and discussion 
KISS1 is a metastasis suppressor protein which must be secreted to suppress metastasis 
(Nash & Welch, 2006). We have previously reported that KISS1 is processed to kisspeptins 
outside of the cell by furin, a prohormone convertase (Harihar et al., 2014). However, processing 
at dibasic cleavage sites does not appear to be critical for metastasis (Harihar et al., 2014). One 
interpretation of these data is that KP54 liberation and KISS1R binding are not necessary for 
metastasis suppression. These observations lead to the possibility that non-KP54 domains of 




Figure 13: Melanosphere formation 1  




































Figure 13: A, Melanosphere formation is inhibited by KMP2-3XFLAG expression, but 
not KISS1 expression. Melanospheres formed by KISS1-expressing cells are larger than 
those formed by vector controls. B, Quantification of total melanospheres formed 
demonstrates extreme inhibition of melanosphere formation by KMP2 expression.  
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that other kisspeptin fragments of KISS1, namely the N-terminal domain (KMP2), possess the 
ability to suppress metastasis.   
However, besides KMP2, multiple kisspeptins suppressed metastasis. Statistically, KMP8 
and KMP10 were the only kisspeptins which did not initially suppress metastasis. The domain 
that these two kisspeptins share is the C-terminal domain of KISS1 (K122-Q145). The presence 
of this domain on KMP8 blocked the seemingly anti-metastatic impact of KP54, which is also 
included on KMP8. KMP10 by itself is a short (~20aa) peptide, but could potentially block 
protein-protein interactions by blocking protein folding dynamics. Subsequently, the KMP10 
domain could prevent successful furin cleavage to liberate the KISS1R binding motif in lieu of 
the remaining protein. KMP10 expression did not suppress metastasis, which could be due to a 
lack of bioactivity of this domain or low expression in KMP10 cells (Figure 1B). The presence 
of KMP10, the C-terminal domain of KISS1 in the two kisspeptins which did not suppress 
metastasis suggests an inhibitory effect of this domain on the metastasis suppressor capabilities 
of KP54.  
One notable observation from this study was validation that KP54 can suppress 
metastasis in murine cells lacking expression of KISS1R. These data support previous 
observations that KISS1 suppresses metastasis in C8161.9 and MelJuSo human melanoma lines 
lacking endogenous KISS1R expression (Harihar et al., 2014; W. Liu et al., 2014; Nash et al., 
2007). Rather than suggesting KP54 does not signal through KISS1R, we instead suggest that 
these data support the hypothesis that KISS1 and KP54 can signal in a juxtacrine manner to 
suppress metastasis. As a secreted peptide, KISS1 is often studied in its ability to signal in an 
intracrine manner. However, the impact of KP54 stimulation on the metastatic microenvironment 
has not been thoroughly investigated. Low levels of KISS1R expression have been reported in 
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lung tissue, which presents a hypothesis for the mechanism of KP54-mediated metastasis 
suppression (Kotani et al., 2001).  These data suggest that KP54 can signal through stromal 
KISS1R as a mechanism of metastasis suppression. Future studies to further define the role of 
KP54 and KISS1R signaling in the metastatic microenvironment would provide a benefit to the 
field.  
Much of this study focused on the characterization of KMP2 as a metastasis suppressor 
peptide. In this work, we have demonstrated that KMP2 expression is sufficient to suppress 
metastasis in vivo, suppress migration in vitro, and elevate mitochondrial mass and function. 
These phenotypes are also observed with the expression of full-length KISS1. We have also 
demonstrated that KMP2 expression without the remaining KISS1 protein is a potent inhibitor of 
melanosphere formation, which indicates that the KMP2 domain may be more potent in its 
suppressor capabilities in lieu of the remaining protein. Because KMP2 does not contain the 
LRF-amide KISS1R binding motif, KMP2 metastasis suppression is independent of KISS1R 
binding. As these phenotypes are present in both in vivo and in vitro assays, this presents the 
hypothesis that KMP2 utilizes an intracrine signaling mechanism of metastasis suppression.  
The data indicate that KMP2 is a potent metastasis suppressor domain of KISS1. 
However, the mechanism by which KMP2 suppresses metastasis remains undefined. As a 
secreted peptide, KMP2 is likely to bind a receptor or other membrane-bound protein to induce 
metastasis suppression.  KISS1 binding to non-receptor proteins has been described in the 
literature. When characterizing MMP9’s ability to cleave KISS1 at Gly-118 and Leu-119, a 
highly stable disulfide binding interaction between KISS1’s Cys-53 and pro-MMP9 and pro-
MMP2.  This cysteine lies within the KMP2 domain, and this binding interaction suggests that 
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other proteins could potentially interact with this region. Further studies identifying the exact 
mechanism of KMP2 metastasis suppression will be necessary.  
KISS1 and kisspeptins are a valuable tool to study in the quest to develop better anti-
metastatic therapeutics. While most chemotherapeutics target both tumors and their metastases, 
these drugs can select for a resistant population of cancer cells. Additionally, conventional 
chemotherapeutics and radiation can have potent side effects, resulting in decreased quality of 
life for patients. KISS1 has potential for use as an anti-metastatic therapeutic, but the short half-
life of proteins makes them poor drugs unless they are a candidate for a stapled peptide. Another 
downside to KISS1 as an anti-metastatic therapeutic is off-target side effects in the 
hypothalamic-pituitary-gonadal axis. KISS1 has been administered therapeutically as a 
stimulator of GnRH, LH, and FSH release (George et al., 2017). Recently, administration of 
KP54 has been found to increase libido and limbic brain activity (Comninos et al., 2017). These 
off-target effects, while not necessarily deleterious, are undesirable when choosing the basis for a 
therapeutic. While the exact mechanism of KMP2 metastasis suppression remains undescribed, 
KMP2 does not signal through KISS1R and would not induce the reproductive side-effects 
consequent of KISS1:KISS1R signaling. Further studies could implicate KMP2 as a basis for a 
stapled peptide therapeutic.  
In conclusion, this study is the first to investigate the metastasis suppressor capabilities of 
KP54 and non-KP54 kisspeptins. We have supplemented the growing literature that identifies 
KP54 as suppressing metastasis through juxtacrine signaling in addition to intracrine signaling 
through KISS1R. Additionally, we found that the N-terminal domain of KISS1, herein referred 
to as KMP2, possesses metastasis suppressor capabilities comparable to that of the full-length 
protein. KMP2 expression alone is sufficient to suppress metastasis in vivo and metastatic 
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characteristics in vitro. These data suggest that, while the mechanism is currently undetermined, 





















Cancer is a disease characterized by genomic instability and abnormal cellular behavior 
(Hanahan & Weinberg, 2011). This genomic instability can lead to broad heterogeneity between 
patients with the same tumor types. This heterogeneity extends to a tumor’s tendency to 
metastasize (Fidler, 1978). From increasing discoveries of new biomarkers and improved 
technology to detect circulating tumor cells, the field is improving in its ability to discern which 
cancers have a propensity towards metastasis (Alix-Panabieres & Pantel, 2014; Faratian & 
Bartlett, 2008; Ransohoff, 2007). However, many of these biomarkers are specific to a certain 
tumor type and reliability varies from biomarker to biomarker (Ransohoff, 2007). There remains 
a need to more precisely target and treat disseminated metastases, as metastasis is at the root of 
most the morbidity and mortality associated with cancer. Drug distribution to metastases can be 
accomplished by most conventional chemotherapeutics, however many of these have harmful 
side-effects such as neuropathy and cardiotoxicity (Bhave, Shah, Akhter, & Rosen, 2014; 
Fehrenbacher, 2015). Additionally, tumors and metastases can grow resistant to initially effective 
treatments (Nakazawa, Paller, & Kyprianou, 2017; Sharma, Hu-Lieskovan, Wargo, & Ribas, 
2017). This gap in therapy leaves a persistent need to develop a better method to discern 
metastatic potential and treat disseminated metastases.   
 One strategy for targeting metastases is to target structures absent in normal tissue. The 
perinucleolar compartment (PNC) is a structure composed of RNA-binding proteins and RNAs 
which is physically associated, yet distinct from, the nucleolus (Huang, Deerinck, Ellisman, & 
Spector, 1997).  Components of the PNC include CDK13, PTB, CUG-BP1, KSRP, Raver 1 and 
2, Rod1, as well as newly synthesized RNA Pol III transcripts for a series of genes (Gromak et 
al., 2003; Philips, Timchenko, & Cooper, 1998; Savkur, Philips, & Cooper, 2001; Valcarcel & 
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Gebauer, 1997). The complete structure and function of the PNC has yet to be thoroughly 
described. The PNC is a dynamic structure which disassembles during mitosis and is 
reassembled during G1 phase, but PNC-negative cells can also give rise to PNC-positive 
daughter cells (Huang et al., 1997). The PNC is found exclusively in cancer cells, and appears to 
be enriched in metastatic cells (Kamath et al., 2005; Norton et al., 2008). A panel of human solid 
tumor cancer cell lines found that PNC can be found in a broad spectrum of cancers (Norton et 
al., 2008). As a cellular structure present in only malignant cells of many cancer types, the PNC 
is a promising candidate for therapeutic targeting. 
 A high throughput screen was performed to identify compounds which target and 
disassemble the PNC (Frankowski et al., 2010; Norton et al., 2009). From this screen, one 
compound, ML246 (hereafter metarrestin), was discovered to efficiently disassemble the PNC 
with low cellular toxicity (Frankowski et al., 2010). Metarrestin was later found to be effective in 
targeting and inhibiting metastases in breast cancer patient-derived xenograph, human prostate, 
and pancreatic cancers (manuscript in preparation). Metarrestin has no discernable impact on 
normal cell populations which harbor no PNC. This potent impact on PNC disassembly and 
targeting of metastatic cells makes metarrestin a lucrative compound with therapeutic potential.  
 Melanoma is an aggressively metastatic cancer with the highest mortality rate of all skin 
cancers (Siegel et al., 2016). In the panel of human solid tumor cancer cell lines, two human 
melanoma cell lines were evaluated and found to be PNC-positive (Norton et al., 2008). This 
observation aligns with the highly metastatic nature of melanoma. From this observation, it is 




 To date, no experiments characterizing the impact of this compound on a melanoma 
model have been conducted. This study evaluated the efficacy with which metarrestin can arrest 
disseminated melanoma metastases. To examine the impact of metarrestin treatment on 
disseminated metastases, a series of experimental metastasis assays were performed in 
conjunction with metarrestin treatment. The impact of metarrestin treatment on orthotopic tumor 
growth was also tested. Cumulatively, this study found that metarrestin treatment attenuated 
primary tumor growth and delayed tumor onset, but had no significant effect on targeting 
disseminated metastases.  This study provides evidence that metarrestin could have an impact on 
treating tumors with low PNC prevalence, but is less effective in treating metastases in PNC-low 
tumor types. 
Materials and methods 
Cell line and culture 
C8161.9 is a highly metastatic sub-clone of the human melanoma cell line C8161 (Welch et al., 
1991). Cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM)/F12 growth 
medium (ThermoFisher Scientific). Growth medium was supplemented with 5% fetal bovine 
serum, 1% L-glutamine, and 0.25% non-essential amino acids. For experiments, cells were 
detached using 2 mM EDTA in Ca2+- and Mg2+-free Dulbecco's phosphate-buffered saline 
(DPBS). Cells were tested and found to be free of Mycoplasma spp. contamination by a PCR-
based assay (ATCC, Universal Mycoplasma Detection Kit).    
Drug preparation 
For treatment, ML246 was suspended in 5% N-Methylpyrrolidine (NMP, Sigma M79204), 20% 
polyethylene glycol-400 (PEG- 400, Sigma 202398) and solubilized via sonication and 
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vortexing. Large drug crystals were disrupted by drawing the mixture through a syringe fitted 
with a 28G needle. This mixture was stored at room temperature. Immediately prior to injection, 
75% total volume 10% HP-β-cyclodextrin was added to the solution.  
Immunofluorescence Staining  
C8161.9 cells were plated on 8-well chamber slides to reach 70% confluence within 24 hours. 
The following day, cells received vehicle or metarrestin treatment at 10uM for 24 hours. Cells 
were fixed using 4% paraformaldehyde and stained for SH-54, which stains for polypyrimidine 
tract binding protein (PTB), a nuclear protein included in the PNC. Briefly, cells were washed 
following fixation, permeablized with 0.1% Triton-100 in PBS, and blocked in 3% BSA. Slides 
were incubated in 1:300 SH-54 antibody overnight, then washed, blocked and incubated with 
secondary antibody conjugated to Texas Red fluorophore. Coverslips were mounted using 
medium containing DAPI for nuclear staining. Slides were imaged and assessed for PNC 
prevalence using fluorescence microscopy.  
Statistics  
Statistical tests were conducted via One Way ANOVA followed by pair-wise post-tests (Shapiro-
Wilk normality test) for experimental groups containing more than two treatment groups. The 
experiment testing metarrestin against macroscopic metastases was analyzed via t-test. The 
spontaneous metastasis assay was insufficiently powered for statistical analysis.  
Animal studies  
Animals used in this study were Hsd: Athymic Nude-Foxn1Nu (Envigo). Animals were 
maintained at 23ºC and given food and water ad libitum.  
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Metarrestin treatment on microscopic metastases  
C8161.9 cells (2x105) were plated 48 hours prior to intravenous injection into the lateral tail 
vein. One week after injection, mice received daily (Monday – Friday) injections of either 
vehicle (5% NMP, 20% PEG-400, 75% v/v 10% HP-β-cyclodextrin), 6.25 mg/kg, 12.5 mg/kg, or 
25 mg/kg metarrestin treatment in a 200 uL injection volume. Mice received injections for three 
weeks until week 5 of the experiment, upon which the mice were euthanized and lungs were 
harvested for evaluation of gross metastases.  
Metarrestin treatment on macroscopic metastases  
C8161.9 cells (2x105) were plated 48 hours prior to intravenous injection into the lateral tail 
vein. Two weeks after injection, mice received daily (Monday – Friday) injections of either 
vehicle (5% NMP, 20% PEG-400, 75% v/v 10% HP-β-cyclodextrin) or 25 mg/kg metarrestin 
treatment in a 200 uL injection volume. Mice received these injections for three weeks until 
week 5 of the experiment, upon which the mice were euthanized and lungs were harvested for 
evaluation of gross metastases.  
Preventative treatment with metarrestin 
 C8161.9 cells were plated to reach 75% confluence in 24 hours. Metarrestin treatment (10uM) 
was administered for 24 additional hours prior to injection, upon which the cells (2x105) were 
injected through the lateral tail vein of nude mice. One treatment group received daily 
intraperitoneal metarrestin treatment (25mg/kg) and the other two groups were monitored until 
the completion of the study.  
Metarrestin impact on orthotopic tumor growth  
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C8161.9 cells were plated 48 hours prior to injection, upon which cells (1x106) were injected 
intradermally into the flank of nude mice. Treatment of either metarrestin (25mg/kg) or vehicle 
was implemented intraperitoneally the day following injection and continued daily for the 
duration of the 6-week experiment. Animals were euthanized and the tumors were measured and 
resected. 
Results 
PNC in C8161.9 are disassembled by metarrestin treatment 
To evaluate the abundance of PNC in C8161.9 melanoma, immunofluorescence was performed 
to stain for PTB (Figure 1). PTB is a nuclear protein which is normally widely distributed 
throughout the nucleus. In PNC-positive metastatic cells, PTB will accumulate in the PNC in 
bright, distinct puncta. C8161.9 cells were stained for PTB and PNC abundance was quantified. 
Despite the highly metastatic nature of C8161.9 cells, the PNC prevalence in C8161.9 is only 
8.2% (Table 1). This level of PNC abundance is relatively low compared to other cell lines 
which have been evaluated (Norton et al., 2008). Following a 24-hour treatment with 10 µM 
metarrestin, PNC were completely disassembled in C8161.9 (Figure 1). These experiments 
illustrated the relatively low abundance of PNC in C8161.9 cells and the efficiency with which 
metarrestin treatment disassembles them.  
Cellular pre-treatment with metarrestin suppresses metastatic outgrowth 
To test whether PNC depletion prior to injection would diminish successful metastatic seeding 
and outgrowth, C8161.9 cells were pre-treated with 10 µM metarrestin for 24 hours. The 
following day, pre-treated and untreated cells were injected into the lateral tail vein of nude mice 
for an experimental metastasis assay (Figure 2). The treatment group receiving exclusively 
83 
 
metarrestin pre- treated cells (n=10) displayed no suppression in metastasis (Figure 3). However, 
the treatment group which received metarrestin pre-treated cells as well as 25 mg/kg metarrestin 
s.i.d. displayed a statistically significant suppression in metastases. The combined effect of pre-
treatment with daily treatments appears to be sufficient to prevent successful metastatic 
colonization and outgrowth. This effect is likely due to an initial sensitization and prevention of 











Figure 1. C8161.9 cells have detectable PNC by immunofluorescence staining for PTB, a PNC 
protein component. Arrows indicate PNC localization. Perinucleolar compartments in C8161.9 





























Table 1. SH-54 staining for PNC in non-treated and vehicle-treated cells demonstrates a low PNC 




No in vivo treatment 
+10μM MA 
In vitro treatment only 












Figure 2. Experimental design to test the impact of metarrestin pre-treatment on cells before 











Figure 3. Impact of metarrestin pre-treatment in cells prior to injection with or without 
subsequent in vivo dosing. While treatment with metarrestin suppresses gross metastasis 
numbers, pre-treatment in conjunction with in vivo treatment has a statistically significant 
depression in metastasis numbers. Groups were compared by One Way ANOVA (P=0.02) 
followed by pairwise comparisons using Holm-Sidak method (Non-treated vs. in vitro and 
in vivo treatment, p=0.05). 
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Microscopic metastases are not suppressed by metarrestin treatment 
Many patients presenting with highly invasive and undifferentiated tumors are likely to harbor 
micro- or macroscopic metastases at the time of diagnosis. To test the ability of metarrestin 
treatment to arrest disseminated microscopic metastases, an experimental metastasis assay was 
performed. Metarrestin treatment commenced seven days following intravenous injection, upon 
which metastases contain roughly 10 cells (John F. Harms & Welch, 2003). Seven days 
following injection, mice received five weeks of s.i.d. intraperitoneal metarrestin treatment at a 
range of doses: 25 mg/kg, 12.5, 6.25, or vehicle (Figure 4). No visible toxicity or signs of 
distress upon treatment were observed in the animals. While metarrestin treatment did trend 
towards lower metastatic load (188 average untreated vs. 138, 126, 142 treated), these results 
were not statistically significant (Figure 5; One way ANOVA, P=0.357). These results suggest 
that metarrestin treatment combined with low abundance of PNC is an inefficient way of 
targeting disseminated microscopic metastases in this model of metastatic melanoma.  
Macroscopic metastases are not inhibited by metarrestin treatment 
For the purposes of this experiment, macroscopic metastases are defined as metastatic lesions 
roughly 100 cells in size. Disseminated metastases are estimated to reach this size two weeks 
after metastatic seeding (John F. Harms & Welch, 2003). These lesions can impede proper tissue 
function and cause a decrease in quality of life. To test the effectiveness of metarrestin treatment 
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Figure 4. Experimental design to test the impact of metarrestin treatment on 











Figure 5. One week following intravenous injection of cells, metastases are estimated to 
be roughly 10 cells. Treatment commenced one week following metastatic seeding with 
metarrestin doses of at 25mg/kg, 12.5mg/kg, and 6.25mg/kg resulted in a trend of 
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Figure 6. Experimental design to test the impact of metarrestin treatment on macro-
metastases. Cells were seeded, left to grow into metastases for three weeks, before receiving 










Figure 7. Three weeks after cell seeding, metastases are expected to be roughly 100 cells. 
Treatment with metarrestin at this established metastasis stage does not have a statistically 
significant impact on metastasis. However, the metarrestin treatment group (left) has a 
lower mean than vehicle-treated mice (right, 118 vs 155) and there was a higher number 




performed. Mice were maintained for three weeks following injection, upon which metastases 
are estimated to be roughly 100 cells in size. At this point, mice received s.i.d. IP injections of 
either vehicle or 25 mg/kg metarrestin treatment (Figure 6). No visible toxicity or signs of 
distress upon treatment were observed in the animals. Compared to vehicle treated mice (average 
number metastases= 155), mice receiving two weeks of metarrestin treatment had a slight 
decrease in metastases (Figure 7; average number of metastases = 118). However, this effect was 
not statistically significant (two-tailed p=0.270, t-test). This treatment regimen combined with 
the advanced nature of these metastases appears to be insufficient to suppress or arrest metastatic 
outgrowth. 
Metarrestin treatment attenuates orthotopic tumor onset and growth 
Although PNC are enriched in metastatic cells, PNC-positive cells are also present in primary 
tumors. Previous studies have indicated high prevalence of PNC in breast cancer tumors, 
suggesting that the primary tumor could also be targeted by metarrestin treatment (Kamath et al., 
2005). To test the ability of metarrestin treatment to suppress growth of orthotopic tumors, cells 
were injected intradermally into the flank of nude mice. The day following inoculation, mice 
received either vehicle or 25 mg/kg s.i.d. IP metarrestin treatment (Figure 8). Mice were 
evaluated for tumor onset and size. Interestingly, metarrestin treatment delayed tumor onset by 
10 days (Table 2; 14 days to 24 days, vehicle vs. metarrestin treated). Additionally, final tumor 
size and weight were suppressed in metarrestin treated animals (Figure 9). These data show that 
even in a PNC-low tumor type, metarrestin treatment can still have a potent effect on delaying 
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Figure 8. Experimental design to test the impact of metarrestin treatment on orthotopic tumor 
formation and progression. Mice were intradermally injected with 1x10
6
 cells and given either 















Figure 9. A, Orthotopic tumor weight of intradermal tumors with daily vehicle or metarrestin 
(25mg/kg) treatment. Metarrestin treatment has a tumor suppressive impact on tumor weight. B, 
Treatment with metarrestin delays tumor onset by 10 days, suggesting that while metarrestin 
treatment delays tumor onset, it does not prevent eventual tumor growth. *Note: No distant 










Table 2. Time to tumor onset in metarrestin or vehicle-treated mice. Times were determined 




This study describes the impact of metarrestin, a molecule which disassembles the perinucleolar 
compartment, and its ability to arrest disseminated melanoma metastases. Metarrestin, which has 
suppresses metastasis in breast cancer PDX, pancreatic cancer, ovarian cancer, and prostate 
cancer, seems to suppress orthotopic tumor growth and metastatic colonization in PNC-positive 
cell lines. These data suggest that in a clinical setting, metarrestin treatment may not be the best 
course of action for patients presenting with a low PNC abundance and a likelihood of 
disseminated metastases.  
 However, not all data from this study were insignificant. Pre-treating cells with 
metarrestin prior to injection coupled with daily metarrestin treatment caused a significant 
suppression of metastasis. Although this scenario is clinically unrealistic, it does shed light on 
possible applications of metarrestin. Prior to metastatic dissemination, pre-treatment with 
metarrestin seemed to decrease cell viability. This initial decrease in viability coupled with daily 
injections of metarrestin seemed to prevent metastatic outgrowth, implying that PNC-positive 
cells can arise from PNC-negative cells. Additionally, this experiment demonstrated that 
preventative metarrestin treatment could be beneficial for patients presenting with very early-
stage tumors.  
 One of the more striking observations from this study was the impact of metarrestin 
treatment on orthotopic tumor onset and growth. Perinucleolar compartment prevalence has been 
demonstrated to increase with tumor progression and in metastatic lesions (Norton et al., 2008). 
Given the low abundance of PNC in C8161.9 cells (8.2%), the effect of metarrestin treatment on 
orthotopic tumor growth was striking. The ability of metarrestin treatment to delay tumor onset 
by 10 days suggests that this treatment regimen was effectively killing PNC-positive cells from 
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the onset of treatment. This treatment appears to select for PNC-negative cells, which appeared 
to be in lower abundance earlier in tumor progression. However, since metarrestin-treated tumors 
did eventually grow, this suggests that metarrestin treatment is ineffective in fully attenuating 
PNC-negative tumor growth.   
 The duration of this experiment did not allow for the observation of disseminated 
metastases in vehicle- or metarrestin-treated animals, but future studies would benefit from this 
experiment. Despite their eventual ability to form tumors, metarrestin treatment appears to keep 
PNC-positive cells at bay. A hypothesis from the results of this study would be that metarrestin-
treated primary tumors will produce fewer metastases than vehicle-treated tumors. As surgical 
resection is one of the more prevalent cancer treatments, an experiment studying the ability of 
metarrestin treatment to suppress outgrowth of seeded metastases would provide additional 
clinical relevance to the study.   
 While there were valuable insights to be learned from this series of experiments, there are 
limitations to its interpretation. To begin, C8161.9 cells have a low abundance of PNC. These 
experiments provide evidence that metarrestin is likely to be ineffective in treating disseminated 
metastases from PNC-low tumors. However, performing these experiments in a melanoma 
model with a higher abundance of PNC would provide more clear data as to whether metarrestin 
could serve as an anti-metastatic therapeutic. An additional limitation to this study is the manner 
of drug treatment. Metarrestin and vehicle treatments were administered by intraperitoneal 
injections Monday through Friday for five weeks following metastatic inoculation. Mice respond 
with stress upon handling by humans, and this has been reported to modify metastatic responses 
to the experimental metastasis assay (Moynihan, Brenner, Ader, & Cohen, 1992). To avoid this 
daily stressor, these experiments could be performed using a surgically implanted osmotic pump.  
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Finally, there exists a challenge in extrapolating studies performed in mice to a human model. 
The experiments examining metastasis bypassed the first half of the metastatic cascade and pre-
selected the metastatic site. Drug delivery to other metastatic sites, such as bone or brain, is 
likely dissimilar from the lung. No toxicity was observed from the dosing paradigm used in this 
study, but human side effects may be different and discourage use. Additionally, the nature of the 
preventative treatment experiment is impossible to recapitulate in a human disease model.  
 In conclusion, this study examined the impact of metarrestin, a PNC-disassembling 
compound, on C8161.9 melanoma tumors and metastases. C8161.9 has a low abundance of 
PNC, but still appears sensitive to metarrestin treatment on orthotopic tumor growth. In addition, 
metarrestin pre-treatment appears to rapidly eliminate PNC-positive C8161.9 cells prior to 
injection, and subsequent metarrestin treatment was sufficient to attenuate pre-treated metastatic 
lesions. Despite the low PNC abundance in C8161.9, this study still observed trends towards 
metastasis suppression following metarrestin treatment. This trend, combined with the potent 
suppression of orthotopic tumor onset and growth, suggests that metarrestin could serve as an 
adjuvant therapy in specific tumor types. In tumors with a high PNC prevalence, metarrestin is 
likely to be an effective adjuvant in conjunction with the standard of care. Another role for 
metarrestin could be in highly aggressive tumor types with low progression-free survival. 
Assuming the low toxicity observed in mice is consistent with a human model, patients with 
highly aggressive tumors could likely benefit from metarrestin treatment. Based on these results, 
further studies are recommended in melanomas with a higher PNC prevalence. These results 
suggest that, in tumor types with higher PNC abundance, metarrestin could be a powerful clinical 








 Metastasis is an insidious process which is responsible for much of morbidity and 
mortality associated with cancer. Methods to therapeutically target metastases often overlap with 
therapies effective at targeting the primary tumor. This paradigm neglects the heterogeneity of 
metastases, and can result in microscopic metastatic lesions which lie dormant before forming 
macroscopic metastatic lesions. The heterogeneity of metastases and the inability to fully 
eradicate them upon treatment with chemotherapy is a lingering problem in the realm of cancer 
treatment. To target metastases in an adjuvant manner, one approach is to target certain features 
which are gained throughout metastatic progression, such as the PNC. Another interpretation to 
solving the problem of metastasis is to re-introduce factors lost in metastatic progression, such as 
metastasis suppressor genes. Therapeutic re-introduction of metastasis suppressors and/or 
targeting of metastases-enriched structures such as the PNC could serve as a strategy for 
adjuvant therapy to prevent successful metastasis.  
Chapter 2: Metastasis suppression by KP54 and non-KP54 kisspeptins 
 KISS1 is a secreted neuropeptide which suppresses metastasis in a broad spectrum of 
cancers (Beck & Welch, 2010; Nash et al., 2007). Upon secretion, KISS1 is cleaved by furin into 
kisspeptins at three dibasic sites (Harihar et al., 2014). This cleavage event releases several 
kisspeptins into the extracellular environment. One of these kisspeptins is KP54, the 
neuropeptide ligand to KISS1R, a Gq/11-protein coupled receptor (Kotani et al., 2001; Muir et al., 
2001; Ohtaki et al., 2001). However, expression of KISS1 has been documented to induce 
phenotypes inconsistent with KISS1R activation, and KISS1 can suppress metastasis in cells 
lacking KISS1R expression (W. Liu et al., 2014; Mitchell et al., 2006; Nash & Welch, 2006). 
These observations beget two hypotheses: that KP54 suppresses metastasis through paracrine 
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signaling, and that other kisspeptins resultant of furin processing are responsible for metastasis 
suppression. This study examined these hypotheses by investigating the metastasis suppressor 
capabilities of all ten kisspeptins resultant of furin cleavage.      
 One observation of note from this study was the observation that expression of KP54 is 
sufficient to suppress metastasis in lieu of KISS1R co-expression. This observation supplements 
the growing body of literature evidencing a stromal or paracrine mechanism of action for KP54-
mediated metastasis suppression. While KP54 was not the focus of this study, future studies are 
advised to further examine the role of KP54 in metastasis suppression. Detectable levels of 
KISS1R have been reported in the stroma of both human and mouse lung tissue (Kotani et al., 
2001). Future studies examining the necessity of stromal KISS1R would further elaborate on the 
relevance of stromal KP54:KISS1R interactions. This could be accomplished by utilizing an 
experimental metastasis assay in KISS1R-deficient or haplo-insufficient mice. Alternately, 
studies investigating the impact of KISS1R agonist (RF9) or antagonist (p234) treatment to 
animals bearing seeded lung metastases would shed further light on the relevance of KISS1R 
signaling in KP54-mediated metastasis suppression.  
 Kisspeptin-54 contains the characteristic RF-amide motif shared by other ligands of the 
neuropeptide family. Recent reports have identified promiscuous in vitro binding activities 
between ligands and receptors of the neuropeptide family, namely neuropeptide FF receptors 1 
and 2 (Lyubimov et al., 2010; Milton, 2012; Milton, Chilumuri, Rocha-Ferreira, Nercessian, & 
Ashioti, 2012; Oishi & Fujii, 2016; Oishi et al., 2011). These neuropeptide receptors are Gs G-
protein coupled receptors highly expressed throughout the central nervous system which 
modulate nocioception (Bonini et al., 2000; Elshourbagy et al., 2000; Hinuma et al., 2000). As 
melanocytes arise from embryonic neural crest cells, a potential explanation for KP54 
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suppressing metastasis in lieu of KISS1R co-expression is the aberrant expression of NPFFR1 or 
2. However, QPCR analysis showed that the levels of NPFFR1 and 2 were low in C8161.9 
human melanoma cells compared to SK-N-MC neuroblastoma control (NEW FIG?). Therefore, 
unless the effect of KP54 signaling through NPFFR1/2 is potent even at low levels, the 
mechanism of KP54-mediated metastasis suppression is more likely resultant of stromal KISS1R 
interactions.  
 The main data of interest from this study were the data demonstrating that non-KP54 
kisspeptins suppress metastasis. Specifically, the N-terminal domain of KISS1, KMP2 in this 
study, was a potent suppressor of metastasis (Figure 2A, Figure 3, Figure 12B). This study is the 
first to not only examine kisspeptins lacking the KP54 domain, but to also characterize their 
impact on metastasis suppression. The N-terminal domain of KISS1 has been herein 
demonstrated to suppress metastasis in vivo, as well as several metastatic characteristics such as 
motility, melanosphere formation, and clonogenicity in vitro. This observation significantly 
redefines the field of study examining KISS1 as a metastasis suppressor by broadening the 
spectrum of metastasis-suppressing domains.  
 This study characterized both the impacts of KMP2 on in vitro characteristics of 
metastasis and on in vivo metastasis suppression. However, within the boundaries of this study, 
the exact mechanism of KMP2-mediated metastasis suppression remains unexplained. As KMP2 
is a kisspeptin liberated outside of the cell by furin cleavage, a hypothesis for the mechanism of 
KMP2 metastasis suppression is that KMP2 is the ligand to a heretofore unidentified cell surface 
receptor. To answer this lingering question, an unbiased genome-wide CRISPR/Cas9 knockout 
screen was performed in KMP2-expressing cells (Appendix 1). Preliminary studies show that 
transduction with this genome-wide knockout library led to a loss of KMP2-induced metastasis 
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suppression (Appendix 1, Figure 2). Deep sequencing of lung metastases from this study will 
reveal genes silenced to recover metastatic proficiency. This study will identify relevant 
signaling molecules involved in the KMP2-mediated metastasis suppression pathway and shed 
light on this novel mechanism of metastasis suppression.  
 While the mechanism of metastasis suppression remains presently incomplete, KMP2 
shows promise as a metastasis suppressor peptide. A translational application of this finding 
would be to use KMP2 as a basis for a therapeutic peptide. Peptides have inherent challenges as 
biological therapeutics, as they can be readily degraded by extracellular proteases. However, the 
field of stapled peptides, or peptide stabilized by a molecular brace, has gathered momentum in 
clinical trials. Staples “lock” peptides into a specific conformation, increase resistance to 
protease cleavage, and enhance cell permeability (Blackwell et al., 2001; Chang et al., 2013; 
Higueruelo, Jubb, & Blundell, 2013). Using KMP2 as a peptide backbone, addition of a staple to 
increase stability could support the concept of KMP2 as a possible anti-metastatic therapeutic 
peptide.       
Chapter 3: Impact of metarrestin treatment on melanoma metastases 
 The studies discussed in chapter three outlined the efficacy of metarrestin, a small 
molecule capable of disassembling the PNC, treatment on disseminated melanoma metastases. 
Metarrestin has been found to be an effective inhibitor of metastasis in breast cancer and 
pancreatic cancer models (manuscript in preparation). In this experimental model of human 
melanoma, metarrestin treatment elicited a modest and statistically insignificant impact on 
metastasis outgrowth. While there was a slight trend towards metastasis suppression, these data 
were insignificant and clinically irrelevant, as metarrestin-treated animals still bore a large 
metastatic load (>100 metastases per animal). These data are not altogether unexpected, 
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however, given that we observed a low (8.2%) prevalence of PNC in C8161.9 (Chapter 3, Table 
1).  
 Given the low abundance of PNC in C8161.9, however, metarrestin treatment was not 
wholly ineffective. Metarrestin treatment suppressed orthotopic tumor onset and growth. No 
visible metastases were observed in the lungs collected from tumor-bearing animals of either 
treatment group (data not shown). Similarly, pre-treatment of cells in vitro prior to cell seeding, 
followed by metarrestin in vivo treatment led to a robust suppression of metastasis. Metarrestin 
treatment in low-PNC models of metastasis may be most effective in larger cell populations 
rather than micro- or macroscopic metastases.  A hypothesis from these data is that metarrestin 
treatment targets PNC-positive tumor cells with a higher propensity to metastasis, and ultimately 
suppresses spontaneous metastasis in this tumor model. To test this hypothesis, future studies 
would extend the timeframe of the experiment to observe for spontaneous metastases from 
metarrestin- or vehicle-treated animals with surgical resection of primary tumors.    
 The low degree of overall metastasis suppression observed by metarrestin treatment in 
the C8161.9 model of human metastatic melanoma does not negate the potential therapeutic 
benefit of metarrestin. Indeed, several challenges exist in the translation of drug development 
from mice to humans. Cell-line derived xenograph models targeting oncogenic proteins have low 
success in predicting efficacy in human treatments (Johnson et al., 2001). These human 
melanoma studies were performed in an immune-compromised mouse model, neglecting any 
possible interplay from the host immune system. Future studies would benefit from examining a 
spontaneous mouse model of cancer and metastasis, such as a MMTV-PYMT or HER2-Neu 
transgenic mouse model of breast cancer. These models would allow for observation of 
metarrestin treatment on spontaneous breast cancer tumors and metastasis in an immune-
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competent animal. Additionally, maximum tolerated dose studies examined doses up to 125 
mg/kg with no visible toxicity, suggesting that increased dosing could improve treatment 
efficacy without additional toxicity to the animals. Further characterization of metarrestin as a 
therapeutic molecule is necessary before moving into human studies.   
Significance 
 These studies have shed further light on the complexity and viability of targeting and 
treating disseminated metastases. The study of KISS1 and its kisspeptin fragments has identified 
a novel metastasis suppressor domain, herein KMP2, and has characterized its ability to suppress 
metastasis. KMP2 is a 56-amino acid peptide capable of suppressing metastasis, enhancing 
mitochondrial function, and decreasing stemness and spheroid formation abilities of metastatic 
cells. This metastasis suppression seems to be completely independent of KISS1R activation. 
Further study of KMP2 and its specific mechanism of metastasis suppression will elaborate on its 
viability as the basis for an anti-metastatic therapeutic.  
 There exists a large and pressing need for better drugs to target metastases. Patients 
diagnosed with more advanced tumors or disseminated metastases generally have decreased long 
term survival. At the point of metastasis, patients are often considered beyond any measurable 
help or benefit of treatment. Treatments which could extend the progression-free survival of 
patients with metastatic cancers with minimal side effects are worthy of further study. Drugs 
which can extend the lifespan or quality of life for patients with advanced disease can be fast-
tracked by the FDA. For example, Palbociclib (Ibrance) is a drug specifically catered to patients 
with metastatic ER+/HER2- breast cancer. This treatment doubled progression-free survival 
when administered in conjunction with letrazole, the standard of care and was subsequently fast-
tracked to FDA approval by the granting of “breakthrough therapy” status. This example 
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demonstrates the potential benefit that anti-metastatic therapies can provide to a patient 
population in desperate need. Metarrestin and KMP2 both serve as examples of molecules with a 
large therapeutic potential which can help patients with metastatic disease. Further study of each 
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Appendix I: A genome-wide CRISPR screen to identify KMP2 metastasis 





 Chapter 2 describes novel anti-metastatic activity by the N-terminal domain of KISS1, 
referred to as KMP2.KMP2 expression was demonstrated to suppress metastasis in vivo, 
suppress migration in vitro, and elevate mitochondrial function in vitro (Chapter 2). These 
characterizations demonstrated that KMP2 suppresses metastasis and metastatic traits in a 
manner comparable to full-length KISS1. This mechanism of metastasis suppression appears to 
be independent of KISS1R expression or stimulation, as KMP2 does not contain the LRF-amide 
binding motif required for KISS1R activation. However, ruling out KISS1R signaling leaves the 
question as to the functional mechanism of metastasis suppression utilized by KMP2. 
 As KMP2 and other kisspeptins are peptide fragments which require secretion to suppress 
metastasis, it is hypothesized that KMP2 signals through a receptor to induce metastasis 
suppression. This mechanism is suspected to be intracrine, as many of the metastasis suppressor 
phenotypes have been described in vitro without stromal interactions. However, receptor 
signaling is not the exclusive mechanism of signaling for extracellular peptides. To avoid the 
inherent bias of specifically investigating receptors, a genome-wide CRISPR/Cas9 knockout 
screen was performed in cells expressing KMP2. The results of this screen suggest that KMP2 
utilizes complex signaling pathways to suppress metastasis.   
Methods and Materials 
Cell lines and culture 
B16F10 is a melanotic melanoma cell line derived from a C57BL/6J mouse. These cells were 
cultured and injected into mice ten times to derive their name and enhanced metastatic 
characteristics (Fidler, 1973). Cell lines were cultured in a 1:1 ratio of Dulbecco’s-modified  
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 minimum Eagle Media and Ham’s F12 media with 5% fetal bovine serum, 1% l-glutamine and 
0.025% non-essential amino acids. Lentiviral constructs of KMP2-3XFLAG were in developed 
in pENTR1A vector through the Life Technologies Gateway platform and then recombined into 
pLenti PGK Puro DEST plasmid for stable expression (Addgene #w529-2). Cells were 
transduced with this plasmid and viral packing particles (Life Technologies ViraPower Viral 
Packaging Mix). To select for expressing clones, cells were transduced and selected with 2.5µg 
puromycin for 14 days. Resistant clones were isolated and tested for expression.  
GeCKO CRISPR/Cas9 plasmid library preparation 
Mouse GeCKOv2 CRISPR knockout pooled library was a gift from Feng Zhang and obtained 
through Addgene (catalog #1000000052) (Sanjana, Shalem, & Zhang, 2014; Shalem et al., 
2014). Both library A and library B were used in this study, ensuring 6X redundancy in gene 
targeting. Libraries were amplified as per depositor’s instructions. Briefly, Lucigen Endura 
electrocompetent cells (#60240) were electroporated, and antibiotic-free bacterial broth was used 
to plate electroporated bacteria on ampicillin agar plates. Plates were inverted and incubated at 
37C overnight. Colonies were scraped and suspended in antibiotic-free broth before pelleting and 
weighing the pellet. DNA was isolated using one column of a Qiagen Maxiprep Spin Kit per 
0.4g bacterial pellet. Plasmids from library A and library B were pooled upon plasmid 
purification.  
Viral Library Preparation 
293FT cells (Invitrogen) were used to generate lentiviral GeCKO library pools. 293FT cells were 
plated to reach 90% confluence. Cells were transfected with 3 µg pooled library plasmids and 9 
µg of equimolar packaging mix (VSV-G and PAX2) using Lipofectamine 2000. Transfection 
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media was applied to 293FT cells and incubated overnight. The following day, transfection 
media was exchanged for fresh complete media. Twenty-four hours later, media was harvested 
and centrifuged at 5000G for 15 minutes at 4C. Viral supernatant was stored in cryovials at -80C 
until transduction.  
Experimental metastasis assay 
B16-F10 KMP2-3XFLAG clone 3 cells were tested for expression and plated in four 25cm 
plates. Three plates of cells were transduced at an MOI of 1 with the GeCKO library virus 
generated from 293FT cells. Cells were transduced, and maintained under selection for 7 days 
until injection. Cells were disassociated and suspended in ice-cold Hank’s Buffered Saline 
Solution. For injection, 200 μl of cell suspension (5.0 x 104 cells) was injected into the lateral tail 
vein of 4-week-old female syngeneic C57BL/6J mice. Four mice received B16-F10 KMP2-
3XFLAG clone 3 control cells to ensure metastasis suppression. Twenty mice received B16-F10 
KMP2-3XFLAG + Library transduced cells. Mice were housed at 23̊ºC and given food and 
water ad libitum for two weeks. Upon euthanasia, gross lung metastases were quantified by light 
microscopy under a dissection microscope. Lungs were imaged and flash frozen using liquid 
nitrogen. Tissues were stored at -80C until processing.   
Tissue preparation and genomic DNA extraction 
200 mg samples from three lungs bearing a high metastatic load (>50 metastases per sample) 
were selected for genomic DNA extraction. DNA extraction was performed as per the 
depositor’s protocol. Briefly, flash frozen tissues were ground using a mortar and pestle and 
digested using NK lysis buffer (50 mM Tris, 50 mM EDTA, 1% SDS, pH 8) and proteinase K 
overnight at 55°C. The next day, 30 µl RNase A (Qiagen) was added to each sample and 
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incubated 25 times before incubation at 37°C for 30 minutes. Samples were cooled on ice before 
adding 2ml chilled 7.5 M ammonium acetate to precipitate proteins. Samples were vortexed and 
centrifuged at 5000G for 20 minutes. Supernatant was decanted into a new tube, to which 
isopropanol was added and samples subsequently inverted. Samples were centrifuged at 5000G 
for 10 minutes. Supernatant was carefully aspirated from genomic DNA pellets and 70% ethanol 
was added to each tube. Samples were inverted and centrifuged at 5000G for 2 minutes. 
Supernatant was removed and carefully aspirated from the genomic DNA pellet. The pellet was 
left to air dry for 1 hour before adding 350 µl of elution buffer to each sample. Samples were 
incubated at 65°C for 20 minutes, then left at room temperature overnight. Samples were 
vortexed briefly and concentration was determined using a Nanodrop (Thermo Scientific). 
Samples were pooled and stored at -20°C for further analysis.  
Library preparation and deep sequencing 
To analyze the distribution of gRNA sequences present in genomic DNA, two steps of PCR were 
performed to amplify samples from pooled DNA samples. First, PCR v2 primers were utilized to 
add PCR priming sites to inserts (Table 1). PCR was performed using 7.5 µG genomic DNA as 
template DNA and Phusion Flash High Fidelity Master Mix PCR cycling conditions 
(ThermoFisher Scientific). Specific conditions for this reaction were annealing temperature of 
55°C and 20 cycles. From the PCR mix, 5µl was utilized for the template basis of PCR#2. 
PCR#2 consisted of an equivalent mix of F1-F12 concatenated ultramer primers containing 
Illumina barcodes and the R1 concatenated primer (Table 2). Reactions were mixed using a 1:1 
mixture of forward:reverse primers in 50 µL reaction volume, using Phusion Flash High Fidelity 
Master Mix. The reaction was cycled for 27 cycles to achieve appropriate band density (Figure 



























Table 1. V2 primers used to add priming sites to CRISPR/Cas9 sequences integrated into 




































































Table 2. Concatenated primers used to amplify CRISPR/Cas9 gRNA inserts from PCR #1 with 
primers from Table 1. Primers contain Illumina barcodes and a staggered sequence variation to 
avoid monotemplate issues during sequencing.   
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using the QiaQuick Gel Extraction Kit (Qiagen) and optimized conditions (Taiwo et al., 2012). 
Isolated DNA was eluted in water and checked for concentration using the Nanodrop.  
 Deep sequencing experimental planning was performed in collaboration with the KUMC 
Genomics Core. The Agilent Bioanalyzer was used to verify the quality of the gel extraction. 
Following this, QPCR was performed to verify the presence of Illumina adaptors on the isolated 
band. Validated samples will be sequenced using the Illumina Rapid Read 150 cycle sequencing 
procedure and a high concentration of PhiX (15-25%). 
Results 
Transduction with GeCKO library disrupts KMP2 metastasis suppression 
Following intravenous injection and two weeks of incubation, lungs were evaluated for 
metastatic load (Figure 1). Mice receiving injections of B16-F10 KMP2-3XFLAG cells 
presented with no detectable metastases (n=4). These results are consistent with previous 
experiments (Figure 1A). However, mice bearing KMP2-3XFLAG + library transduced cells 
displayed a broad spectrum of metastatic load (Figure 1B). Four animals had zero metastatic 
burden. The remaining 16 animals bore a metastatic load. These data support the inherent 
redundancy in the GeCKO system. These data also support the hypothesis that there are several 
signaling effectors crucial to KMP2’s mechanism of metastasis suppression, possibly through 
receptor activation or other means.  
GeCKO sequences are detectable in lung metastases 
Using isolated genomic DNA from three lungs bearing a high metastatic load, PCR was 
performed in two rounds to amplify the gRNA inserts from metastases. The first round of PCR, 
using v2 adaptor primers (Table 1) added priming sites to sequences. The second round of PCR  
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Figure 1: A, Representative photos of lungs from animals injected with B16-F10 KMP2-
3XFLAG cells. These lungs bear no metastatic load. B, Representative lung photos from animals 
injected with B16-F10 KMP2-3XFLAG + library cells. Metastatic lesions vary in size. Most 































Figure 2: Agarose gel (2%) containing PCR products of PCR from two separate conditions: #1-
2) 5 and 7.5 μg of genomic DNA input from PCR#1 reaction using 2X PCR Master Mix 
(ThermoFisher Scientific) and #3-4) 5 and 7.5 μg of genomic DNA input from PCR#1 reaction 





further amplified gRNA inserts and added Illumina adaptors to flank gRNAs (Table 2). The 
expected product from these consecutive rounds of PCR is 370 bp. This band was obtained and 
purified for sequencing (Figure 2).   
Conclusions and future directions 
 The findings of this study indicate that KMP2 suppresses metastasis through an 
undoubtedly complex signaling pathway. Sequencing information produced from this study will 
be used to identify silenced genes present in metastases expressing KMP2-3XFLAG. Studies 
utilizing genome-wide knockout screens have been performed in both in vitro and in vivo 
platforms (Katigbak et al., 2016; Shalem et al., 2014). Results from this study will shed light on 
the mechanism of KMP2 metastasis suppression, but also genes which can regulate metastasis 
and override metastasis suppressor signaling. 
 Genes identified by this experiment are likely to be relevant KMP2 signaling effectors. 
However, the sheer volume of metastases detected suggests the presence of off-target hits. 
Despite the potent anti-metastatic impact of KMP2 expression, silencing of genes such as pro-
apoptotic factors (Bcl-2 family proteins, caspases, etc.) or tumor suppressor genes (p53), or 
additional factors may be sufficient to overcome suppression. In order to discern off-target gene 
hits from KMP2 signaling gene hits, a number of strategies will be employed. Analysis of 
sequencing results will commence with determining the number of hits per gene identified. 
Genes targeted more frequently in more metastases will receive more attention during analysis 
due to abundance. Special attention will be given to cell surface molecules and receptors 
identified by this screen, due to the secreted nature of KMP2 and the hypothesis that KMP2 
binds to a receptor to induce metastasis suppression. Next, pathway analysis will be performed 
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on the sequencing data set to identify signaling pathways shared by the identified genes. These 
strategies will stratify the data to define off target hits from KMP2-related hits.  
 Following the identification and characterization of impacted signaling pathways, these 
hits must be functionally validated. To confirm these hits, individual genes at the initiation of 
impacted signaling cascades will be targeted for knockout and rescue studies. Additionally, 
receptors and cell surface molecules identified by this screen will be selected for further analysis. 
Individual CRISPR/Cas9 targeting vectors will be developed to target these selected genes, and 
these knockouts will be developed in KMP2 expressing cells. Following the development of 
these knockout lines, cells will be injected into mice via experimental metastasis assay to 
evaluate metastatic efficiency. If these genes are critical for metastasis suppression, the silencing 
of the individual gene in the presence of KMP2 should be sufficient to prevent metastasis 
suppression. Subsequently, a rescue plasmid will be introduced into knockout lines which does 
not contain the CRISPR/Cas9 gRNA target sequence to recover expression of the gene of 
interest. These clones will be used to perform additional experimental metastasis assays to 
validate the recovery of metastasis suppression.  
 In conclusion, this study has conducted an unbiased genome-wide CRISPR screen to 
identify signaling pathways involved in KMP2-induced metastasis suppression. The data 
generated by this study indicate that there are a broad number of signaling effectors critical for 
metastasis suppression. These studies will further elaborate on the mechanism by which KMP2 
suppresses metastasis.  
 
 
